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ABBREVIATIONS 
WHO – World Health Organisation. 
IHD – Ischemic Heart disease. 
CHD – Coronary Heart disease 
CVD – Cardio Vascular disease 
IMA – Ischemia Modified Albumin 
CK-MB – Creatine Kinase – MB isoform 
LDH – Lactate dehydrogenase 
AST – Aspartate transaminase 
ECG – Electro Cardiogram 
WHO – World Health Organization 
MI – Myocardial infarction 
TC – Total cholesterol 
TAG – Tri acyl glycerol 
HDL – High density lipoprotein 
VLDL – Very low density lipoprotein 
LDL – Low density lipoprotein. 
 
 
 
 
STUDY OF SERUM LEVEL OF ISCHEMIA MODIFIED ALBUMIN IN 
ACUTE CORONARY SYNDROME: 
ABSTRACT: 
BACKGROUND: 
Ischemic heart disease is the greatest single cause of mortality and loss of 
disability-adjusted life years worldwide. Early identification and management 
of patients with acute myocardial infarction reduces the mortality 
phenomenally. Along with ECG and other clinical parameters, cardiac 
biomarkers do have an important role in the early diagnosis and   management 
of patient with ACS. This study purposes to study the role of Ischemia modified 
albumin as a early marker of myocardial ischemia. 
AIM AND OBJECTIVE: 
To measure Serum Ischemia Modified Albumin  within 6 hours of onset   of 
chest pain  and to correlate the IMA values with CK-MB, LDH, TGL, T-CHOL, 
HDL, LDL & VLDL. 
MATERIALS AND METHODS: 
The study was conducted in Thanjavur Medical College Hospital.  50 patients 
with symptoms of acute coronary syndrome presented within 6 hours  of onset 
of pain in the causality  with  ECG findings correlated  and   were taken as 
subjects . 50 age and sex matched controls  were taken as control group.  Blood 
samples were subjected to estimation of IMA (ACB test) , CKMB, LDH, SGOT  
and lipid profile. 
RESULTS: 
The mean value of IMA for control and study group were 37.67±14.74 and 
115.07±17.55 respectively . The  Mann Whitney U score was .000 and p value 
.000 (<0.01) . Spearman correlation showed significant correlation of Ischemia 
modified Albumin  with  CK-MB, lipid profile and  LDH. 
CONCLUSION:  
The results of the present study confirm the findings of previous studies, that 
reported that the Albumin Cobalt colorimetric assay distinguishes myocardial 
ischemic patients from non ischemic patients (p<0.001). IMA assay presents a 
quantitative accurate laboratory determination of the  occurrence of an Ischemic 
myocardial event  including  angina of various types. Measurement of Ischemia 
Modified Albumin levels  diagnose Acute Coronary Syndrome in patients with 
ongoing myocardial ischemia in Emergency Department. Measuring IMA  
along with ECG and other markers improves the diagnostic sensitivity of the 
method. 
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INTRODUCTION: 
Acute coronary syndrome (ACS) is an umbrella term for a wide spectrum of 
clinical signs and symptoms suggestive of myocardial ischemia.
1
 Myocardial 
ischemia denotes decrease in oxygen and nutrient supply to the cardiac 
myocytes due to inadequate blood perfusion. Myocardial infarction refers to cell 
death due to prolonged ischemia.
2
 
Ischemic heart disease is the greatest single cause of mortality and loss of 
disability-adjusted life years worldwide.
3
 Further a substantial portion of this 
burden falls on low- and middle-income countries. Following are the factors 
which underline the importance of developing newer diagnostic and therapeutic 
strategies for this disease:  
1. Epidemiology of the disease 
2. Economical , social and legal liabilities for clinicians 
3. Lethal consequences of the disease.4 
Notwithstanding this, early identification and management of patients with 
acute myocardial infarction reduces mortality phenomenally
5
. The traditional 
clinical approaches such as detailed history, careful  physical examination and 
ECG findings are helpful in stratifying the patients but it seems to be inadequate 
in early definitive diagnosis in many of the cases.
6
 
,7
 Along with ECG and other 
8 
 
clinical parameters, cardiac biomarkers do have an important role in the early 
diagnosis and   management of patient with ACS.  
The term ‘biomarker’, an abbreviation for “biological marker” is defined 
as a characteristic substance in serum or any body fluid which can be 
objectively measured and recognised as an indicator of normal biological 
processes, an important component or event of the pathogenic processes or 
pharmacological responses to therapeutic interventions.
8
 While a single 
biomarker sometimes covers this role in certain diseases, in multifactorial 
diseases like coronary artery disease (CAD), the task of identifying the 
biomarkers is an ongoing task.
9
 
ACS starts when there is disruption of atherosclerotic plaque in the 
coronary artery, causing occlusion of the vessel preventing myocardial 
perfusion and stimulating aggregation of platelets and formation of thrombus. 
Data from recent studies emphasises that the rupture of a vulnerable plaque 
which is unstable and its associated inflammatory changes as the reason for 
impaired perfusion rather than impaired blood flow in response to narrowing of 
the arteries due to thickening of the preformed plaque.
10,11,12
 
The contractility and the electrical stability of the myocardial cells need 
oxygen and adenosine 5β-triphophate (ATP). As the myocardial perfusion 
decreases gradually  the following changes or phases takes place.  
9 
 
1.  ISCHEMIC PHASE: In this phase, both aerobic and anerobic 
metabolism take place in the cells. 
2. INJURY PHASE: When there is continuous decrease in perfusion, 
aerobic metabolism fails and subsequently anaerobic metabolism also 
becomes significantly reduced. 
3. NECROSIS OF THE MYOCARDIAL CELLS: Myocardial necrosis 
with irreversible damage proceeds when  perfusion is not restored in 
about 20 minutes.
13
  
 
The cardiac biomarkers currently in wide use in clinical practice like creatine 
kinase (CK) and its fraction CK-MB, troponins, myoglobin and natriuretic 
peptides are markers of myocardial necrosis which happens at the downstream 
of the pathophysiology of ACS.  
Recent investigations are directed towards analysing components involved in 
processes upstream from necrosis, such as components released during 
ischemia, components of plaque destabilisation and rupture, factors of 
thrombosis, molecules of inflammation and acute phase reactants for earlier 
assessment and risk stratification and indexing them under “biomarkers”.  
10 
 
Apart from being sensitive, an ideal biomarker of myocardial injury should be 
cardiac specific, easily measurable and accurate, thereby influencing therapy 
and improving patient outcome.  
Ischemia modified albumin(IMA) is a U.S. Food and Drug Administraion 
approved biomarker for acute ischemia. The N terminus of albumin is damaged 
when exposed to ischemic conditions, making it unable to bind metals thus 
enabling it to be measured using albumin cobalt binding test.
14,15,16
 The levels of 
IMA increase within minutes of onset of ischemia- implicating it in the early 
detection of acute ischemia before the onset of necrosis.  
This study purposes to study the serum  levels of Ischemia modified albumin as 
an early marker in myocardial ischemia. 
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AIM: 
To measure the serum levels of Ischemia Modified Albumin in paitents with 
ACS presenting within 6 hours of onset of chest pain. 
OBJECTIVES :- 
(1) To correlate the IMA values with CK-MB 
(2) To correlate the IMA values with LDH 
(3) To correlate the IMA values with other markers of atherosclerosis like 
 Total cholesterol 
 Triacylglycerol 
 High density lipoprotein 
 Low density lipoprotein  
 Very low density lipoprotein  
(4) To prove the use of IMA as an early marker of myocardial ischemia. 
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REVIEW OF LITERATURE: 
Ischaemic heart disease (IHD) is a clinical syndrome which occurs due to 
underperfusion  caused  by reduced blood supply to the cardiac musculature.
17
 
Impairment or disturbances in the coronary blood flow due to atherosclerotic 
narrowing is the commonest cause but can also occurs due to arterial spasm. 
(Warrell et al, 2004). 
The term “acute coronary syndrome” (ACS) includes  a range of thrombotic 
coronary  artery diseases, including unstable angina (UA) and both ST-segment 
elevation (STEMI) and non-ST-segment elevation  myocardial infarction 
(NSTEMI).
18
 
EPIDEMIOLOGY: 
Over the last decade, cardiovascular disease (CVD) stands for the single largest 
cause of death worldwide. According to World Health Organisation (WHO) 
global report, in 2004, 17 million deaths and 151 million disability – adjusted 
life years (DALY) were caused by CVD. The prevalence of risk factors for IHD 
has increased in the developing world as a result of urbanisation and it has been 
predicted that the prevalence of IHD is rising and IHD is most likely to become 
the most common cause of death worldwide by 2020. 
20,21
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APPLIED ANATOMY 
 Heart is a hollow muscular organ located in the mediastenum resting on the 
diaphragm. It is enclosed by a covering called pericardium. The cardiac walls 
comprises of three layers - Peicardium, Mesocardium and Endocardium, from  
external to internal. It consists of four chambers- two atrias and two ventricles. 
Of these ventricles especially left ventricle are thicker than the atrias.  
BLOOD SUPPLY: 
The right and left coronary arteries originating from the aortic sinuses provides 
blood flow and nutrient perfusion to the heart. These arteries gives off 
subsequent larger to smaller  branches from epicardium to endocardium  of 
which endocardium is the layer most susceptible to ischemia because its 
perfusion relies on the smallest branches. 
The myocardium is made of bundles of striated muscle fibers the alternate 
contraction and relaxation of which enables the functioning of the heart. These 
fibers contains  proteins like cardiac specific contractile proteins, regulatory 
proteins, enzymes and proteins for energy use.  They are called actin and 
myosin troponins, and  myoglobin, creatine kinase, lactate dehydrogenases 
respectively  and these proteins are used as cardiac markers.  
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CARDIAC METABOLISM 
The mechanical pumping and the regulation of intracellular and trans- 
sarcolemmal ionic movements and concentration gradients require continuous 
supply of oxygen approximately 15% of that of the organism  and energy in the 
form of ATP. 
The energy need of the heart depends on the following: 
 Developing tension,  
 The rate of contractions and  
 The level of contractility . 21 
ATP production in the cardiac muscle takes it source mainly from glucose and 
free fatty acids which are supplied from plasma, cell store (glycogen) and from 
lipolysis of adipose tissue respectively. There is a reciprocal relation between 
the utilization of these two principal sources of acetyl CoA in cardiac muscle. 
Both glucose and free fatty acids are broken down into acetyl coA  inside the 
cytoplasm and mitochondria respectively which eventually enters the TCA 
cycle inside the mitochondria to yield  the energy source ATP . these ATP 
enters into the cytoplasm and use for various physiological purposes.  
In the fasted, resting state, the main source of acetyl COA (70%) will be the  
circulating FFA  and their  uptake are high. In the fed state, blood glucose and 
15 
 
insulin, glucose oxidation increases and FFA oxidation decreases subsequently.  
Factors which increases the myocardial glucose uptake from glycogenolysis and 
glycolysis are increased cardiac work, the administration of inotropic agents, 
hypoxia, and mild ischemia.  
During stress  the adrenergic stimulation cause increased circulating levels of 
FFAs and its metabolism in favour of glucose. But in despite the breakdown  of 
more glycogen and glucose breakdown , only lactic acid is produce from 
glucose (anerobic glycolysis) which donot enter TCA cycle. Moreover , 
ischemia inhibits the cytoplasmic enzyme pyruvate dehydrogenase.  As a result 
less ATPs are produced by these anaerobic glycolysis than aerobic glycolysis 
which leads to production of pyruvate and subsequently oxidized to CO2.
22
 
The sequence of events when adrenergic stimulation superimposed on 
myocardial ischemia are.  
 Adrenergic stimulation and severe ischemia 
 Reduce oxidative phosphorylation 
 High concentrations of circulating FFAs 
 Wastage of ATP 
 Decreased  ATP content   
 Dysfunctional  myocardial contraction. 
16 
 
Creatinine phosphate is the main source of energy which will be in equilibrium 
with ATP.  In reduced energy state , creatine phosphate stores declines first.
23
 
Conditions requiring increased myocardial energy. 
1. Hypertrophy of cardiac muscle,  
2. Fibrosis, 
3. Increased heart rate, 
4. Increase in  wall tension due to ventricular dilatation,  
5.  Intracytoplasmic  calcium [Ca2+] increase  
Creatine phosphate is the source of energy stored in the myocardium. This is in 
balance with ATP which is the immediate source of energy. CP stores are the 
first to decline when there is reduced availability of energy. There is an elevated 
need for myocardial energy when there is hypertrophy of the cardiac 
musculature, fibrosis, increased heart rate, dilation of the ventricles due to 
increase in the tension of the cardiac walls and increased Ca
2+
 in the 
intracytoplasmic compartment. Ischemia can be worsened or cardiac failure can 
be precipitated when there is mismatch between the demand and production of 
myocardial ATP which can occur in the event of diminution of coronary reserve 
due to impeded coronary flow culminating from as a result of abnormal 
microcirculation and/or obstruction.  
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FACTORS INFLUENCING MYOCARDIAL O2 SUPPLY AND 
DEMAND
24
 
I.MYOCARDIAL OXYGEN SUPPLY:   
Coronary blood flow: 
1.  Coronary perfusion pressure    
2. Coronary vascular resistance    
3. External compression 
4. Intrinsic regulation 
 Local metabolites 
1. Endothelial factors 
2. Neural innervations      
II. MYOCARDIAL OXYGEN DEMAND 
1. Wall stress 
2. Heart rate 
3. Contractility 
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 III. SECONDARY PRECIPITANTS OF MYOCARDIAL ISCHEMIA: 
1.  INCREASED MYOCARDIAL OXYGEN DEMAND. 
Fever 
Thyrotoxicosis 
Tachycardia  
Malignant hypertension 
Pheochromocytoma 
Aortic stenosis 
High output status 
Pregnancy, drugs: cocaine, amphetamine. 
2.  DECREASED OXYGEN SUPPLY 
Anemia  
Hypoxemia 
Carbon monoxide poisioning 
Poycythemia  
Hyperviscosity syndromes 
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CLINICAL PRESENTATIONS OF IHD 
The following clinical presentations can be encountered due to reduction in the 
blood flow to the cardiac musculature. 
25
 
 Angina pectoris   also known as Chronic stable angina  
 Myocardial infarction and unstable angina (Acute coronary syndromes  ).   
 Silent myocardial ischaemia (Chronic ischaemic heart disease ) 
 Sudden cardiac death 
ANGINA PECTORIS: 
This is a clinical presentation of Ischemic Heart Disease consisting of  
symptoms of discomfort or pressure in the precordial area which occurs as a 
result of temporary disruption of blood flow to the cardiac musculature not 
progressing to overt infarction. This is characteristically exacerbated by 
physical exercise and mental stress while rest and nitroglycerin used 
sublingually relieves it.
26
  
 Angina pectoris results when there is a mismatch between the demand for 
O2 which increases due to increased workload of the heart and the ability of 
the coronary arteries to supply the same as a result of narrowing. 
Atherosclerosis, coronary artery spasm or in rare instances, embolism of the 
coronary artery can cause such narrowing of the coronary artery. While 
angina can be precipitated by acute coronary thrombosis which  usually 
causes myocardial infarction. 
20 
 
Myocardial O2 demand usually rises with increase in mainly heart rate, 
contractility and tension of the cardiac wall during cardiac systole. A 
narrowing of the coronary vessels in this scenario results in the exaggerated 
mismatch between supply and demand and results in angina. The angina is 
relieved with rest since the demand no more exists.  
Conditions like systemic hypertension, stenosis of the aortic valve, aortic 
valvular insufficiency and hypertrophy of the cardiac muscle increase the 
work load of the heart. Irrespective of the presence or absence of 
atherosclerosis, these conditions can precipitate angina. These disorders also 
increase the myocardial mass thereby decrease the diastolic flow and 
effectively cause reduction in the relative myocardial perfusion.  
PRINZMETAL ANGINA:  
Prinzmetal's or Prinzmetal angina which is also known as  variant 
angina, angina inversa, or coronary vessel spasm) is another type of 
presentation  of myocardial ischemia  typically characterised by chest pain at 
rest (angina) usually occurs in cycles. In contrast to angina induced by 
narrowing of blood vessels due to atherosclerosis  this type of pain is due to 
 vasospasm, a narrowing  of  the coronary arteries  which is  caused by 
contraction of the smooth muscle tissue in the vessel walls. 
27
Abnormal 
constriction of the conductance vessels can cause severe ischemia in 
Prinzmetal’s angina  epicardial coronary arteries are capable of constriction 
21 
 
and relaxation, in healthy persons they serve  as conduits and are referred to 
as   conductance vessels, while the intramyocardial arterioles normally 
exhibit changes in tone and are therefore referred to as resistance vessels . 
Abnormal constriction of the conductance vessels can cause severe ischemia 
in Prinzmetal’s angina 
ISCHEMIC CARDIOMYOPATHY 
Patients with IHD can also present with cardiomegaly and heart failure 
secondary to ischemic  damage of the left ventricular myocardium that may 
have caused no  symptoms prior to the development of heart failure; this 
condition is  referred to as ischemic cardiomyopathy. 
ACUTE CORONARY SYNDROME: 
The term ACS has been introduced as a new clinical phenotype. It  
adequately describe the full range of clinical manifestations resulting from 
atherosclerotic coronary plaque, fissuring or rupture leading to myocardial 
ischemia after incomplete or complete coronary artery thrombotic occlusion. 
 
 
 
 
 
22 
 
SUSPECTED ACS: 
When signs and symptoms on admission suggest underlying myocardial 
ischemia but definitive objectives still lacking. It is the combined evidence of 
ECG, and cardiac bio markers that refines the diagnosis. 
Whenever the perfusion in the coronary arteries decreases due to 
atherosclerosis, there is a fall in the O2 tension in the myocardium. This causes 
temporary disturbances in the biochemical, electrical and mechanical milieu of 
the heart musculature. Therefore normal muscle contraction and relaxation is 
instantly disrupted due to sudden development of intense ischemia which may 
occur in total or subtotal coronary blockage. The subendocardium of the heart 
has poor vascular perfusion and the ischemia is more severe in this portion of 
the wall of the heart.   
The disruption of coronary vessel atherosclerotic plaque results in 
aggregation of platelets and formation of thrombus inciting the chain of events 
culminating in ACS. The thrombus occluding the vessel with subsequent 
reduced myocardial perfusion and not the coronary artery narrowing which is in 
response to thickening plaque, as believed in the past, is the primary reason for 
impending  blood flow that leads to ischemia. Further, an unstable, vulnerable 
plaque rupture with added inflammation, has also been stipulated as cause of 
decreased myocardial perfusion.
28 
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CLASSIFICATION 
ACS can be classified on the basis of changes in ECG  and the increase or 
decrease of cardiac biomarkers. Further, classifying ACS on the basis of ST 
segment elevation as NSTEMI and STEMI is beneficial since they differ in the 
treatment required and prognosis . 
1. STEMI - ST-segment elevation MI or transmural MI  
2. NSTEMI -  Non–ST-segment elevation MI or  subendocardial MI 
3. Intermediate syndrome Unstable angina or acute coronary insufficiency 
or preinfarction angina 
UNSTABLE ANGINA (also called as preinfarction or acute coronary 
insufficiency or intermediate syndrome)  characterised by: 
 Prolonged angina at rest (existing more than 20 minutes) 
 New onset of  angina which has occurred newly with the severity of class 3  
in the Canadian Cardiovascular Society (CCS)  
 Recurring and increasing   angina  which was already diagnosed recurring 
with increasing frequency, severity and duration or lower threshold            
(eg, increased to at least CCS class 3 or  by ≥ 1 CCS class or 2). 
Transient ECG changes like depression or elevation of ST segment, or 
depression of T wave can occur in unstable angina. But it is only transient. If at 
all cardiac markers are elevated it is only a slight increase in the high sensitivity 
24 
 
Troponin tests (hs-cTn), whereas markers like CK are not elevated. MI, 
arrhythmias or even sudden death can occur following unstable angina. 
29,30
 
NON–ST-SEGMENT ELEVATION MI (subendocardial MI  or NSTEMI )  
This type of  myocardial infarction will be characterised by  increased levels of  
cardiac markers in serum like  troponin I or troponin T and CK but  without  the 
appearance of  Q waves or acute ST-segment elevation.  And also ECG changes 
like  depression of ST-segment, inversion of  T-wave , or both may be present. 
ST-SEGMENT ELEVATION MI (STEMI or transmural MI) This type of  
myocardial necrosis  are characterised by the  changes in  ECG which shows 
ST-segment elevation  usually  not rapidly  reversed by nitroglycerin or 
evidenced  by the presence of  new left bundle branch block and  Q waves may 
possibly present.  Further elevation of  specific Cardiac markers like troponin I 
or troponin T and CK are found to be elevated. 
MI also can be classified into 5 types based on etiology and circumstances: 
 Type 1:  Spontaneous MI as a result of ischemia caused by  prime coronary 
event presenting  after   rupture of an atherosclerotic plaque or erosion or 
fissuring or coronary dissection) 
 Type 2:   Ischemia due to increased O2 demand  (eg, hypertension), or 
decrease in  oxygen supply caused by   spasm of coronary artery  or 
embolism or  hypotension  or arrhythmia 
25 
 
 Type 3:  Sudden unexpected cardiac death 
 Type 4a:  Myocardial infarction  eventually with Percutaneous Coronary 
Intervention (PCI) 
 Type 4b:  Thrombosis of documented stent  presenting with myocardial 
infarction 
 Type 5: Myocardial infarcation after Coronary Artery Bypass Grafting 
(CABG)
31,32
 
 
RISK FACTORS FOR ACS: 
33
 
UNMODIFIABLE RISK FACTORS ARE: 
 Race 
 Age 
 Male gender 
 Genetic factors 
 Low birth weight. 
 Family history. 
 Previous history of CVD 
PARTIALLY MODIFIABLE RISK FACTORS ARE: 
 Post menopausal oestrogen deficiency. 
 Diabetes 
26 
 
 Chronic renal diseases. 
 Infection. 
 Stress. 
 Personality 
 Socioeconomic status 
 Microalbuminuria 
 Chronic inflammatory. 
 Lipoprotein (a). 
MODIFIABLE RISK FACTORS ARE: 
 Metabolic 
 Hypercholesterolemia 
 Inflammation 
 High plasma fibrinogen 
 Low  HDL 
 Hyperinsulinemia and insulin resistance. 
 Hyper triglyceridemia 
 Small dense LDL 
 Visceral obesity 
 Hypertension. 
 Hyperhomocysteinaemia 
27 
 
 Behavioural 
 Smoking 
 Low physical activity. 
 Alcohol intake > 89g/day 
AGE Vs ACS: 
Post mortem evidences have demonstrated fatty streaks and also advanced 
lesions in the second decade of life which usually do not become clinically 
evident until the fifth or sixth decades. Experimental models of atherosclerosis 
showed that some of the lesions are reversible to some extent.  Increasing 
prevalence of atherosclerosis among young people may be partly due to increase 
in cholesterol concentration and other coronary risk factors as the age advances. 
The relative risk with increasing cholesterol is steeper in young. The prevalence 
of coronary and aortic atherosclerosis increases with age.
34
  
  GENDER:  
Generally many studies have shown that women presenting with acute ischemic 
syndromes are most  likely  to be older than men  and also more likely to have a 
history of  any medical problem like  hypertension or  diabetes or angina or 
congestive heart failure. The reason is that they are less likely to be smokers or  
to have had a history of  prior infarction. Women have more percentage of HDL 
cholesterol than men which is due to the action of oestrogens and it seems to be 
28 
 
vascular protective also. Post menopausal periods are associated with a rise in 
plasma LDL cholesterol ,fall in HDL cholesterol  and increasing visceral 
adiposity  increases the   risk for CHD .  And also ST elevations are 
significantly lower in females than in males, but unstable angina was 
significantly higher than that of men.  Women were shown to be less likely 
associated with occlusive thrombus even after adjusting for baseline differences 
that is ST elevation with infarction.  But  the relative protection in female 
gender becomes lower if they have diabetes.
35,36,37,38
 
FAMILY HISTORY:  
A family history of premature CVD in an important risk factor.    Familial 
tendency to atherosclerosis and ACS are   almost certainly polygenic.  Family 
history is   particularly important contributor to risk in men   in the lowest 
quintiles for calculated CHD risk .   In women, age-adjusted risk is increased 
almost three fold if either parent has CHD before 60 years of age. Moreover risk 
factors like hypertension and diabetes mellitus are more inclined to   genetic 
susceptibility. 
38
 
 DIABETES MELLITUS:  
 Many patients admitted in hospital with with acute coronary syndromes (ACS)  
were associated with hyperglycaemia. Hyperglycemia has been shown to 
predict the survival and the risk of complications in both diabetic and non-
diabetics. When compared to patients admitted with normal glucose 
29 
 
concentration there is  70% increase in the relative risk in patients  admitted 
with plasma glucose more than 180mg/dl. Both diabetes and impaired glucose 
tolerance are important risk factors for CVD and epidemiological data  have led 
to the notion that diabetes confers a  similar risk of a cardiovascular  event to a 
prior myocardial infarction.   Diabetic patients with  high haemoglobin A1c is  
possibly related to an increased  CVD risk.
40
   
 In a study done by Foo et al ,  a near-linear relationship was demonstrated  
between higher levels  glucose levels on admission  with the    rate of left 
ventricular  failure and cardiac death  due to ACS among 2127 patients. 
Meier et al  also have demonstrated the occurrence of  higher long-term 
mortality rates with  larger infarct size  among hyperglycaemic AMI patients 
with or without diabetes. 
42
 
 Stranders  and  Wahab et al  have also shown the associated risk of admission 
hyperglycaemia with   AMI patients devoid of previously known diabetes. 
METABOLIC SYNDROME: 
The clustering of several coronary risk factors ( high triglycerides, low HDL. 
Obesity, hyperuricemia, hyperinsulinemia and hypertension) has been known 
for several decades .  Reaven proposed the existence of a syndrome with a 
common underlying metabolic defect. At any particular level of coronary risk 
based on the Framingham and PROCAM algorithms, patients with metabolic 
syndrome appear to have higher event rates than predicted.
43
  
 
30 
 
 CHRONIC KIDNEY DISEASE(CKD):   
 CKD patients are prone to have   high prevalence of arteriosclerosis  and  large 
arteries remodeling due to vascular calcification. Reduced Glomerular Filtration 
Rate (GFR) have linear relationship  with a high prevalence of CVD risk factors 
and a higher prevalence of CVD surrogates  and  clinical CVD. More recently,   
the extent of demonstrable angiographic coronary disease reflects the level of 
kidney function in patients with CKD. For example, women with chest pain 
undergoing angiography, an increased creatinine of 1.2 to 1.9 mg/dL is an self-
determining  predictor of significant angiographically proved  coronary disease, 
with  luminal narrowing of 50%.
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STRESS:   
Mental stress is one of the principle  precipitating factor for angina and 
myocardial ischemia in patients with underlying coronary artery disease. 
Myocardial oxygen demand is increased by sympathetic activation which is 
characterised by tachycardia ,high  blood pressure and increase in myocardial 
contractility which further increases the myocardial oxygen demand. Although 
stress induces increased blood flow, s  in  the presence of  atherosclerosis  there  
will not be adequate increase in regional coronary blood flow  inspite of   
increase in the blood pressure- heart rate product and  plasma norepinephrine 
levels.
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PERSONALITY:  
Type A behaviour increases  the risk of coronary heart disease twice than  in 
otherwise healthy men. In 1950s  it was shown  as an significant risk  factor in 
coronary Disease by cardiologist Meyer  Friedman and his coworkers.  Type A 
personalities are charactised  by  set of  features of being insecure about one’s 
status impatient, hostile , time conscious,  highly  competitive, and aggressive 
and incapable of relaxation.
46
  
LIPIDS AND LIPOPROTEINS: 
The association between plasma lipids and coronary heart disease is positively 
correlated in many studies and was   continuous , exponential and showed no 
threshold  , even at low concentrations. Also the distributions of plasma total 
cholesterol concentrations among  patients with and without CHD overlap to a 
considerable degree.   Plasma  apolipoprotein B   (apo B)  concentrations  are 
more discriminating and a few clinical studies have used apo B concentrations 
as the basis for treatment. 
An inverse relationship between plama HDL  concentrations and CHD  risk has 
also been demonstrated in various studies. Clinical experiments on protective 
effects of HDL have been supported  by animal models, in which expression of 
human apo-AI has been shown to inhibit the development of  atherosclerotic 
lesions.  The beneficial effect of HDL  may in part be due to its antioxidant 
properties associated with an intrinsic paraxonase I (PON I ) activity.
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 Low 
PON I activity is an self-sufficient predictor of new coronary events and its 
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polymorphism is reported to be associated with increased lipid peroxide 
hydrolysis. Recent data do support a role for triglycerides as an independent  
risk factor.  Concentrations of  plasma triglycerides above approximately  
1.7mmol/L are associated  with the formation of the more atherogenic , small , 
dense LDL and also it has proatherogenic effects by promoting a procoagulant 
state, being associated with enhanced factor VII activity.
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LIPOPROTEIN (a):  
Apolipoprotein(a) gene determines the plasma levels of Lp(a) and its variability 
genitically .  Therefore  apolipoprotein(a) gene  appears to be  ideal for use in  
Mendelian study of randomization for  evaluating the relationship between  
permanent genetically elevated levels of plasma  Lp(a) and  CVD. (18)  This 
helped to establish a direct relationship between atherosclerosis due to increased 
LDL cholesterol levels and CVD. 
THOMBOGENESIS AND CLOTTING FACTORS: 
Thrombin utilises  fibrinogen as the substrate for the  final step in cascade of 
coagulation. It is also necessary for platelet aggregation, modulation of 
endothelial function to  promote smooth muscle proliferation. A recent systemic 
review has shown that plasma fibrinogen concentration is moderately strongly 
associated with CHD. The relationship between plasma  fibrinogen and 
coronary risk may underlie the positive association between plasma viscosity 
and CHD.
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The tissue factor release is caused by the  endothelial injury  which in turn, 
activates the intrinsic clotting  cascade. Platelet activation and aggregation are 
crucial processes in atherothrombogenesis, and platelet reactivity has been 
reported to be elevated in subjects with diabetes  and unstable angina. There  
exists  a balance between the formation of clot and its inhibition and dissolution 
by factors such as proteins C and S and plasmin. The effectiveness of the 
fibrinolytic system depends on the balance between tissue plasminogen 
activator (tPA) and inhibitors of plasminogen activator converts plasminogen to 
plasmin, which acts on fibrin causing clot dissolution. This process is inhibited 
by PA-I , high concentrations of which are associated with high risk for 
reinfarction. Evidence from Framingham study indicates that plasma PA –I 
concentrations rise with increasing systolic and diastolic pressure. 
Atherosclerotic leions from diabetic subjects have been shown to contain high 
concentrations of PA- I  and plama PA- I is strongly associated with several 
CHD risk factors including body mass index (BMI), lipids and alcobol intake 
and these effects appear to be cumulative. 
Apolipoprotein(a) is a glycoprotein that has structural homologies with 
plasminogen. It is attached to apo B by a disulphide bond and in some 
individuals, comprises the major cholesterol rich lipoprotein. The structural 
similarities between apo(a) and plasminogen have led to the proposition that 
Lp(a) inhibits plasmin activity , leading to a prothombotic state. Plasma 
concentration of Lp(a) are largely genetically determined, but can be modified 
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to a limited degree, by dietary fatty acids, oestrogen and lipid lowering agent 
like  nicotinic acid.  
 
HYPERINSULINEMIA AND INSULIN RESISTANCE: 
 
 Insulin resistance refers to the  decreased rate of  glucose uptake mediated by 
insulin. It was shown to be accompanied by  increased levels of insulin  and 
undesirable changes in cardiovascular risk factors like   high level of 
triglycerides, decreased  HDL cholesterol, and development  of  hypertension. 
Cross-sectional studies have reported  that  insulin resistance is associated with 
atherosclerosis which is ultrasonographically viewed in the absence of 
dyslipidemia and  hypertension. It has been proposed that 11β hydroxysteroid 
dehydrogenase  present in omental adipose tissue  generates  cortisol and causes 
cushingoid distribution of fat under the influence of hypeinsulinemia.  IN 
addition, adipose tissue is now recognized to be a source of a number of 
inflammatory cytokines (interleukin – 6 ) , tumour nerosis factor α(TNF α ), 
growth factors (heparin binding epidermal growth factor (HB-EGF)  hormone 
like substances (leptin, adiponectin, resistin).
50
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HYPER TRIGLYCERIDEMIA:   
Hypertriglyceridemic state promotes  the oxidative and proinflammatory  milieu  
enhancing expression of adhesion molecule  formation of foam cell and 
intoxication of  smooth muscle cell . Following hydrolysis,   chylomicrons 
which are  exogenously derived , VLDL cholesterol secreted endogenously 
enriched remnant by products enters the endothelial space. 
Hypertriglyceridemia increases reverse cholesterol transport It has been 
reported that 10%  lowering of TGL concentration decreases the risk of CHD by 
23%.
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HYPERTENSION: 
 Cardiovascular risk increases both with increasing systolic and diastolic 
pressure.  Plasma cholesterol  is a continuous variable like blood pressure  and 
there is no comprehensible cut-off value, but hypertension doubles the risk of 
CHD at any given concentration of cholesterol. Because  intrasubject blood 
pressure measurements can vary so much over time , the diagnosis of 
hypertension relies on the measurement of blood pressure on several occasions. 
Blood pressure increases with age and its prevalence varies with ethnicity.  
Moreover hypertension is associated with obesity and dyslipidaemia 
contributing to the augmented risk of CVD. 
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HYPERHOMOCYSTEINAEMIA:  
Homocysteine , a  sulphur containing aminoacid, derived from methionine, the 
concentration of which is modulated by dietary vitamin B6, B12 and folate. The 
normal plasma homocysteine concentration is 5 - 15µmol/L. Very high 
concentration of homocysteine (> 100 µmol/L) is toxic to endothelial cells and 
contributes to premature vascular disease due to free radical mediated 
mechanism. High concentration of homocysteine inhibits Nitric Oxide (NO) 
indirectly by stimulating superoxide anion production from endothelial cells. 
Furthermore it increases the atherogenecity of Lp(a) by liberating free apo(a) 
impeding fibrinolysis. There is a dose dependent increase in cardiovascular risk 
with rising plasma homocysteine concentration, synergistic with other coronary 
risk factors and a number of established coronary risk factors are associated wth 
raised concentrations of homocysteine, including smoking and renal 
impairment.
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SMOKING: 
Cigarette smoking was a well known  independent predictor of fresh coronary 
lesion .An alteration in NO biosynthesis accounts for  both primary and 
secondary effects on the initiation  and progression of atherosclerosis.  The well 
known risk factors such as Smoking, poor diet, and lack of exercise  contributes  
to the occurrence of  coronary heart disease.
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  Several studies have shown  that  
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Cigarette Smoking causes about 20% to 25% raise in the leukocyte count in the 
peripheral smear.
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 The increased susceptibility  for smoking associated atherosclerosis and multi 
vessel CAD  is due to  CYP1A1 MSP polymorphism and  certain endothelial 
NO synthase intron 4 polymorphisms. 
Smoking cessation is effectual in the secondary prevention of coronary  heart 
disease. A recent systematic review have shown that  continuous 3 to 7 years 
after smoking cessation in persons with known coronary heart disease  was  
30% decrease in crude risk rate of death and myocardial infarction (MI). 
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LOW PHYSICAL ACTIVITY : 
   
Sedentary life style with reduced physical activity leads to an early development 
of CHD.  Regular physical exercises increase the concentration of HDL and 
decrease both body weight and blood pressure which are beneficial to 
cardiovascular health. Recent data indicate that approximately 30min/day of 
moderate exercise is required to have a significant impact on coronary risk. 
Exercise –based rehabilitation for patients with CHD is effective in reducing 
total mortality and lipid concentration.
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OBESITY: 
Obesity is a well known risk factor for CHD and also growing in prevalence 
throughout  developed and developing  countries world wide. Body mass  is  
positively related to fasting triglycerides concentrations, plasma cholesterol and 
blood pressure, and inversely related to HDL- cholesterol. It is the central or 
visceral  obesity , measured as waist circumference , that is most strongly 
related  to insulin resistance and CHD risk. Waist circumference is a 
significantly better index of   insulin resistance than either waist/hip ratio or 
BMI. A cut off value for waist circumference of  <100 cm rules out  insulin 
resistance in both male and female with optimal sensitivity and specificity.   
Greater the weight gain more is the risk of hyper tension, CHD and  insulin 
resistance diabetes mellitus . Body mass index of > 30 Kg/m2 is considered as 
“obesity” and it  plays a major role in atherosclerotic progression.56,57  
 
ALCOHOL INTAKE:  
Studies have proved that consumption of  more than 89 g/day of alcohol showed  
high prevalence  of CVD.
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  Several population studies have reported that the 
relationship between ethanol consumption and CHD risk is J-shaped , with a 
nadir for risk at approximately three units(30mL) of ethanol per day. Alcohol 
consumption increases the plasma lipid parameters like triglycerides,  VLDL 
and the large, buoyant LDL subfraction , rather than small, dense  LDL which 
contributes to a proatheroenic state. 
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INFLAMMATION  AND INFECTION: 
Atherosclerosis   involves many mechanisms similar to a chronic inflammatory 
disease, the course of its evolution being characterised by T lymphocyte and 
macrophage  permeation. The potential stimuli to   inflammatory process 
include   homocysteine, oxidized LDL , infectious micro-organisms  and the 
free radicals generated from cigarette smoking.  In the absence of neutralisation 
of these insults, persisting inflammation results, which might  cause  local and 
systemic release of cytokines and growth factors.  This is followed by 
thickening of the intimal layer due to stimulation of  extracellular matrix 
elaboration  and smooth muscle cell migration and proliferation. The activated 
leucocytes release IL- 1β and IL-6 which leads to   increase in  hepatic CRP 
synthesis.  
Over   the history of  few years, there exists an increasing interest of utilization 
of markers of inflammation to predict the events of acute coronary disease. To 
some extent the predictive value of these markers perhaps related to their 
capability in recognizing patients with vulnerable plaques rich in activated 
leukocytes. It has been found that high concentration of CRP in plasma is a 
stronger risk factor than elevated von Willebrand factor or Erythrocyte 
Sedimentation Rate (ESR) but has been found to be weaker than passive 
smoking or elevated cholesterol.  
It has been found recently that CRP is deposited in those regions of human 
coronary vessels which are rich in lipid. CRP has the ability to induce 
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chemotaxis in monocyte. Hence it is followed by recruitment of monocytes. 
CRP also activates complement. There is a relationship between the levels of 
CRP and basal NO synthesis by endothelial cells. All this suggests that CRP 
may be involved in the early phases of atherosclerosis pathogenesis.  
The role played by infectious micro organisms in the development of 
atherosclerosis is debatable. Over the last few decades, micro organisms like 
Helicobacter pylori and Chlamydophila pneumonia have been implicated in the 
pathogenesis of artherosclerosis and it has been postulated that treatment of 
patients with antibiotics may decrease the risk of artherosclerosis. These micro-
organisms have been found in the plaques in human beings  and those with 
acute coronary syndrome have been found to have higher titers of antibodies to 
these organisms.  
Autoimmune mechanism has also been implicated in the pathogenesis of 
atherosclerosis. Some micro-organisms elaborate proteins called chaperonins or 
heat shock proteins – 60 (Hsp 60). These are homologous to a protein 
synthesised in the vascular endothelium. It is postulated that an immune 
response mounted against this protein may react with endothelial heat shock 
proteins resulting in injury to the endothelium. Autoimmunity has been 
postulated as the link between atherosclerosis, endothelial dysfunction and 
infection.  Chlamydia, Cytomegalovirus and Herpes are some of the infectious 
agents suspected to contribute to atherosclerosis.
59
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ATHEROSCLEROSIS : 
DEFINITION 
Atherosclerosis is a chronic, degenerative, inflammatory condition affecting 
medium sized and large arteries coupled with  lipid deposition and matrix 
proteins in the arterial wall, ultimately causing narrowing of the lumen of the 
arteries. 
An atheromatous plaque is characterised by a raised lesion with a soft, yellow 
grumous core of lipid  (chiefly cholesterol and cholesterol esters)  covered by a 
firm, white fibrous cap.  Atherosclerotic plaques deteriorate the underlying 
media beside  obstructing blood flow, and can  also undergo  rupture resulting 
in  acute thrombosis.
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PATHOPHYSIOLOGY: 
The origin and progression of atherosclerosis were explained by several 
hypothesis which are not mutually exclusive. Moreover many experimental and 
clinical observations are shown how processes explained in one theory are 
linked to those in another.  
 THE LIPID OXIDATION HYPOTHESIS 
 MONOCLONAL HYPOTHESIS 
 REACTION TO INJURY HYPOTHESIS 
 ENCRUSTATION HYPOTHESIS 
 INSUDATION HYPOTHESIS: 
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INSUDATION HYPOTHESIS: 
The significant events of atherosclerosis points to focal accumulation of fat 
inside the  vessel wall which explains the presence of lipid derived from plasma 
lipoproteins dependable with the role of serum  lipids as risk factor for 
myocardial infarction. This hypothesis not completely explains the pathogenesis 
since lipid deposition though it is necessary for plaque formation but not 
sufficient to explain atherosclerosis. 
Low density lipoprotein (LDL) are too large (20 nm diameter) to penetrate the 
tightly closed endothelial junctions. However , transport transversely into  an 
intact endothelium both  by receptor- mediated uptake of lipoprotein and  by 
nonspecific uptake in to micropinocytic channels are possible .Lipid may be 
engulfed by macrophages and transported into the vascular wall and 
transmigrate between dysfunctional endothelium. 
 
ENCRUSTATION HYPOTHESIS: 
This hypothesis explains the deposition of blood materials such as fat, smooth 
muscle cells and Extra Cellular Matrix (ECM) on the inner surface of the 
arteries leading to the inner wall thickening.  Experimental studies of 
hyperlipidemic animals and autopsy studies of children show that mural thrombi 
do not initiate atherogenesis but it is a critical part of delayed  evolution of 
atherosclerotic lesions which is the  foremost event leading to vascular 
occlusion particularly in coronary arteries. 
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REACTION TO INJURY HYPOTHESIS:  
This hypothesis suggests that the proliferation of smooth muscle  depends on 
discharge of polypeptide growth factors secreted by endothelial cells (ECs), 
macrophages and smooth muscles which accumulate at  the injury site. It also 
explains the cellular responses that occur during atherosclerogenesis constitute 
fibroproliferative and   inflammatory response to injury which led to the 
discovery that platelet derived polypeptides eg: fibroblast growth factor , 
transforming growth factor –β ,thrombin, LDL, endothelin, etc.,  that are 
required for growth of smooth muscle. 
MONOCLONAL HYPOTHESIS: 
Studies have established that many plaques are monoclonal, originating from 
one or very few smooth muscles. The monoclonality of the fibrous cap indicates  
that some indefinite etiologic factor may induce the formation of fibrous cap by 
changing growth control of  smooth muscle cell in the arterial wall. 
THE LIPID OXIDATION HYPOTHESIS: 
 Nitric oxide decay is accelerated by increased production of reactive oxygen 
species,   the  production of which is augmented by  prolonged  hyperlipidemia,  
predominantly hypercholesterolemia . Macrophages of ECs produces oxygen 
free radical which  induces the accumulation of  oxidised lipoproteins  and it 
take up the oxidised LDL particles via the scavenger receptor leading to the 
formation of foam cells. Ultimately , oxidized LDL is cytotoxic to ECs and 
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SMCs leading to EC  dysfunction through stimulation of  liberation of growth 
factors, cytokines and chemokines by ECs and macrophages which in turn 
enhances the recruitment of monocytes into the lesions.  
 
STAGES OF ATHEROGENESIS: 
Stage1:  Chronic endothelial injury 
Stage 2:  Accumulation of lipoproteins 
Stage 3:  Resultant inflammation and factor release  
Stage 4:  Recruitment  of  Smooth muscle cell  followed by  proliferation and     
ECM production 
 
THE ROLE OF CHRONIC ENDOTHELIAL INJURY: 
  The inflammatory processes mediating the endothelial dysfunction is 
usually inactivated by the  laminar pattern of blood flow in the lesion protected 
areas of the vessel wall. Hemodynamic disturbances like low shear stress and 
areas of turbulent flow make the ECs liable for atherosclerosis. Chronic 
endothelial injuries which lead to endothelial dysfunction are usually unnoticed 
and   starts from first decade of life.  This leads to increase in permeability, 
adhesion of leukocyte  and  high thrombotic potential. Accumulation of 
lipoproteins mainly LDL, with its high cholesterol content in the vessel wall 
occurs. Lesional lipoproteins are modified by oxidation of the amino group of 
the lipoprotein leading to the formation of aldehydes.  Migration of monocytes 
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into the intimal layer and transformation into macrophages and lipid filled foam 
cell  follow the  adhesion of monocytes to the endothelium .This eventually 
results in the platelet adhesion, discharge  of factors from macrophages, 
activated platelets and vascular cells leading to the  migration of smooth muscle 
cells into intima  from media and  smooth muscle proliferation  and 
amplification of extracellular matrix causing  accumulation of collagen as well 
as  proteoglycan.
62,63
   
ROLE OF INFLAMMATION: 
  Adhesion of  leukocytes is not supported by the endothelium of  normal blood 
vessels.  Expression of selective adhesion molecules(IL-1 , TNF) in the 
presence of  atherogenesis, helps in leukocyte binding. Macrophages also 
generates many cytokines like monocyte chemotactic protein – (MCP - I) which 
recruits many leukocytes in the plaque. 
ROLE OF LIPIDS: 
Mutations yielding defective apoliproteins causes dyslipidemia predisposing to 
the formation of atheromatous plaque.  Furthermore, conditions like Nephrotic 
Syndrome, Alcoholism , Hypothyroidism  and Diabetes Mellitus also causes 
dyslipidemic state which inturn leads to  the formation of atherosclerotic plaque. 
ROLE OF SMOOTH MUSCLES: 
 Smooth muscle cells migrate from media in to intima undergoes  proliferation 
and deposits ECM components changing  a fatty streak in to a mature fibrofatty  
46 
 
atheroma. ECM growth factors like  PDGF, FGF, TGF – α  helps in this 
process. 
 
HIGH RISK PLAQUES:  
They have  
a. An active inflammatory environment – intrinsic and systemic 
b. A thin fibrous cap with a large lipid core filled with procoagulant 
substances 
c. Endothelial denudation and fissuring caused due to release of 
metalloproteinases 
d. Local high shear stress, usually at branching points 
 
COMPLICATED ARTHEROSCLEROTIC PLAQUES: 
Progression of a simple fibrofatty artherosclerotic plaque to a complicated one 
can occur due to: 
a. Calcification occurring in necrotic areas and elsewhere in the plaque 
synchronised by osteoblast and osteoclast like cells  present in the vessel 
wall, 
b. Mural thrombosis resulting from turbulent flow around the plaque 
causing damage to the endothelial lining making it non thromboresistant  
c. Structural and functional changes making it vulnerable to destabilisation 
and  
47 
 
d. Destabilisation of an atheroma, often leading to acute coronary 
syndromes,  occur possibly  due to mural thrombus  or  fibrous cap 
rupture or hemorrhage inside the plaque. 
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COMPLICATIONS  DUE TO  ATHEROSCLEROSIS: 
The size and location  of the affected vessel and the chronicity of the process are 
the determinents of  further complications.  
a. Sudden occlusion:  Abrupt occlusion of the myocardial arteries may 
occur due  to  the thrombosis   resulting in ischemic necrosis of the tissue 
supplied by the vessel.  
b. Chronic narrowing of the vessel lumen: Growth of the plaque impinges 
on the lumen leading to progressive reduction in blood flow to the tissue 
causing chronic ischemia.  
c. Aneurysm formation: Extension of the complicated lesion of 
artherosclerosis  into the media of an elastic artery proceed to the    
weakening of the wall ultimately ending in the  formation of aneurysm.  
d. Embolism:  Detachment  or dislodgement of thrombus produced over an 
atherosclerotic plaque.  
If the rupture leads to total thrombotic occlusion in the coronary vessels, the 
event is usually an STE AMI. If lesser degrees of occlusion occur, an NSTE 
AMI or UA may ensue. 
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SYMPTOMS OF ACS: 
 Severe chest pain  at sternum,  mostly radiates to the jaw and to the 
shoulders to one or both arms 
 Tightness around the chest radiating to the left arm and  to the left angle 
of the jaw.  
 Nausea , vomiting 
 Diaphoresis  or sweating  
 Dyspnoea or Shortness of breath. 
 Atypical  chest pain ( experienced in different ways or even being 
completely absent which is more likely in  diabetic female patients.   
 Anxiety 
 palpitations  
  Angor animi ( sense of impending doom)   
 Feeling acutely ill.64 
ECG ABNORMALITIES: 
ECG changes occur due to inability of cells affected by ischemia and necrosis to 
produce normal electrical activity. Various ECG changes like conduction 
abnormalities, arrhythmias and ST- T abnormalities may occur. ST-T 
abnormalities may range from peaking of T waves in the  hyperacute phase , 
elevation of ST segment  also known as injury current , inversion of T wave and 
ST segment depression . Damage to the specialised conduction tissues like sinus 
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node, AV node and other tissues may result in conduction disturbances. While 
most of these changes are temporary, some may become permanent.
65
  
 
                      
   
 
DIAGNOSIS OF AMI: 
   
1. World Health Organisation (WHO) criteria for an acute myocardial 
infarction (1986):  Presence of atleast two of the following 
a) Complaints  suggestive of coronary ischemia for a prolonged 
period.(> 30 minutes) 
50 
 
b) Evolutionary changes on sequential ECG indicative of myocardial 
infarction. 
c) An increase or decrease  in serum cardiac markers steady with 
myocardial ischemia or myocardial necrosis. 
2. Criteria for the Definition of Acute Myocardial Infarction (European 
Society    of Cardiology/American College of Cardiology (2000 updated in 
2007 (Global task force)) 
a. Detection of rise and / or fall of cardiac biomarkers ( preferably 
troponin) above 99 
th
 percentile of the upper reference limit  along 
with evidence of ischemia in addition to  atleast one of the 
following: 
i. Symptoms suggestive of ischemia 
ii. ECG changes of fresh ischemia ( new ST-T changes or new 
Left Bundle Branch Block (LBBB)  
iii. Evidence of  pathological Q waves on ECG 
iv. Imaging based  evidence of recent loss of viable 
myocardium or latest  regional wall motion abnormality  
4. Diagnosis of  Established Myocardial infarction: Anyone of the following 
criteria satisfies the diagnosis of established MI 
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a. Appearance of  new pathologic Q waves on consecutive ECGs. 
The patient may  or  may not recollect the  symptoms.  Normalised 
biochemical markers of myocardial necrosis depending on the 
length of time that has passed.  
b. Pathologic findings of  a healed or healing MI.  
Apart from clinical and ECG findings cardiac biomarkers have become 
indispensable in the diagnosis of AMI. 
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CARDIAC BIOMARKERS. 
The term ‘biomarker’ , an abbreviation for “biological marker” is defined as a 
trait that can be objectively measured and evaluated as an indicator of normal 
biological processes , an important component or event of the pathogenic 
processes or pharmacological responses to therapeutic interventions. 
FDA Definition of Biomarker: 
 “Any measurable diagnostic indicator that is used to assess the risk or  
presence of disease.” 
Morrow and delomos criteria for biomarkers: 
1.  Accurate repeated measurements at reasonable cost 
2. Must provide additional information. 
3. Should aid treatment. 
The History of Cardiac Biomarkers 
 The first cardiac biomarker which was found to be elevated was Aspartate 
transaminase (AST)  in 1954 and used in clinical practice those days. Lack of 
specificity and  the presence of  Aspartate transaminase in heart, liver, skeletal 
muscle, kidneys and brain directed its use currently  as a clinical  marker for liver 
damage.   
In 1959, plasma creatine kinase(CK), was found to be elevated in response 
to myocardial damage, which catalyses the  shift of high energy bond from 
creatine phosphate to adenosine triphosphate but it demonstrated high sensitive 
index  for skeletal muscle.  
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In 1960, lactate dehydrogenase (LDH)  came into play and it catalyses the 
reversible oxidation of lactate to pyruvate. However, LDH is found in all cells 
and  like AST, is very nonspecific.  CK was considered to  be more specific than 
either LDH or AST  because those with dysfunction in hepatic system  low levels 
of CK in the liver are less confounding. 
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 In 1979,  despite of  this specificity , especially in patients having muscle and 
hepatic dysfunction WHO had recommended CK, AST and LDH as the 
biomarker components for diagnosis of AMI. 
Identification and categorisation of isoenzyme of  both CK and  LDH  were 
made available through electrophoresis. CKMB have four fractions of 
isoenzymes of which  CKMB levels  were found to be high in cardiac muscle 
(25–30%)  against  skeletal muscle  which was only 1%  comprising of  mostly 
CKMM. Later on, CKMB, CKMB fraction or CKMB/CKMM ratio  
measurement appeared  to be more specific marker for AMI.   
Like CKMB  LDH also have four isoenzymes of which cardiac muscle is 
rich in  LDH 1 (HHHH) and LDH 2 (HHHM)  skeletal muscles contain contains 
primarily LDH 4 and 5. Presence of more H units represents well oxygenated 
state while during the injury phase there is a reduction in ratios of H units.  
Although the measurement of both CKMB and LDH  lack specificity lacking in 
specificity, a revolution in the  detection and estimation was made by the 
emergence of immunoassays incorporated into technical advanced automation  
using polyclonal antibodies and with monoclonal antibodies in 1980s.Monoclonal 
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antibodies  are used in the  measurement of CKMB mass which  enabled rapid  
and  earlier detection of myocardial damage and was also more sensitive and 
specific than the original CKMB activity assay. However, skeletal muscle injury , 
non-ischaemic cardiac disease and some  malignancies  also showed  increase in 
CKMB mass. 
Since CKMB was non- specific , tests with better performance were sought 
for. The   identification of troponin was a crucial advancement in this scenario.  
Though cardiac as well as skeletal musculature harbour troponin, cardiac isotypes 
like cTnI and cTnt  differ from those in the skeletal muscle owing to the presence 
of additional aminoacids on the N-amino terminal which makes them easily 
identifiable. In 1970s, Troponin was discovered to be a constituent of muscle 
myofibril. Only in the late 1980s, efficient radioimmunoassays became available 
for cardiac troponin. Though the use of CKMB as a marker of myocardial 
necrosis had aleady been proposed its superiority to CK and CKMB had not been 
elucidated. In 2000, cTn was declared to be the preferred biomarker in the 
guidelines for AMI diagnosis. Initially there was a increase in the ‘positive’ rate, 
but the assay was not standardised and the association between histopathology 
and cTn was not clearly elucidated. As a result it was met with scepticism. But it 
eventually turned to acceptance in a widespread manner. There also arose an 
acknowledgment of the variablity in the assay. Therefore cut off values with 
coefficient of variation of <10% were recommended to be employed. Now 
recommendations suggest  99
th
  percentile which  is lesser than the levels 
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previously used in practice. But guidelines for such a precision were unachievable 
by many present assays. 
 
CLASSIFICATION OF BIOMARKERS IN ACUTE CORONARY 
SYNDROME:
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ESTABLISHED MARKERS 
1.  Troponin I 
2. Troponin T 
3. (BNP)Brain Natriuretic Peptide  
4.  N – Terminal Pro – BNP 
5. C-Reactive protein  
6. Cystatin C 
7. Heart – Fatty acid Binding Protein. 
EMERGING MARKERS: 
1.  Myeloperoxidase  
2. Metalloproteinase 
3. Soluble CD40 ligand 
4. Ischemia Modified Albumin 
5. Pregnancy associated plasma protein-A 
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BIOMARKERS UNDERSCORING DIFFERENT FACETS OF THE 
PATHOPHYSIOLOGICAL AND OUTCOMES OF ACS 
1.  INFLAMMATION 
 C- Reactive protein 
 Myeloperoxidase 
 Matrix metalloproteinase 
 Soluble CD40 ligand 
2.  PLATELET ACTIVATION 
 Soluble CD40 ligand 
3.  VULNERABLE PLAQUE 
 Pregnancy – associated plasma protein-A 
 Myeloperoxidase 
 Placental growth factor 
 Matrix metalloproteinase 
4. MYOCARDIAL NECROSIS  
 Creatine phosphokinase and isoenzymes 
 Troponin  I and T  
 Fatty acid binding protein 
 
5. ISCHAEMIA 
 Ischaemia Modified Albumin 
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6. PUMP FAILURE 
 Brain Natriuretic peptide 
 NT- pro Brain Natriuretic peptide 
 
CARDIAC TROPONINS: 
Cardiac  troponins T and I are the principal cardiac  regulatory proteins that 
control the calcium mediated interaction between actin and myosin. Troponins 
are released from myocytes when irreversible damage occurs. It is highly 
specific to cardiac tissue and almost accurately diagnoses myocardial infarction 
with a history of ischaemc pain or ECG changed reflecting ischaemia. Serum 
cTnI and cTnT  estimations are better  expressing  more sensitivity and 
specificity to cardiac musculature and in the recognition of damage in the 
myocardium.   Monoclonal antibodies against the  epitopes of both are used in 
the measurement of cardiac troponins. 
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CREATINE PHOSPHATE – MB:  
Creatine Kinase (CK) which is a  muscle enzyme  exists in three isoenzymes. 
CK-MM (skeletal muscle), CK-MB(myocardium) and CK-BB (brain). Around 
90% of CK-MB  are present in the myocardium but trace amounts are found in 
small intestine , tongue, diaphragm and uterus . These isoenzymes are present in 
the cytosol and aid in the transfer of high energy phosphates into and out of 
mitochondria , thus helps in regeneration of ATP in  the cells. In human 
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myocardial biopsy material, concentrations of CK-MB  have been reported to be 
100 fold greater in patients  with aortic stenosis, coronary artery disease etc. The 
pathophysiological basis for increase in CK-MB is by creating a state of 
myocardial hypoxia which causes heart to respond to increased workload by 
increasing its mass and thus leading to its elevation.
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MYELOPEROXIDASE (MPO): 
Inflammatory cells like activated neutrophils and monocytes inside the 
atherosclerotic plaque  produces MPO which acts as a  mediator enzyme. MPO  
is known to induce oxidative damage of tissues  by generating reactive oxidised 
intermediates . Low density lipoprotein (LDL) isolated present inside the  
atherosclerotic lesions  found to have  increased levels of such intermediates. 
MPO expression levels are  reported  at sites of rupture of the plaque , 
superficial erosions and in the lipid core in patients followed with  sudden 
death. Whereas little MPO expression were found  fatty streaks of less harm. 
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C – REACTIVE PROTEIN: 
CRP  is  an acute phase reactant  produced  in response to interleukin (IL-6)in 
the liver . It is very stable pentamieric protein and its concentration  in the 
serum  can  increase many folds during the acute phase response. In January 
2003, CRP was recommended as an inflammatory marker for recognition of 
cardiovascular risk by  both the Centre for disease Control and Prevention 
(CDC) and the American Heart Association (AHA). The high sensitive CRP 
assay (hs-CRP)  was  developed originally to aid evaluation of conditions 
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associated with inflammation in otherwise healthy patients. Identification and 
stratification of  patients  used   Cardiac CRP (cCRP)  assays to assess the  
future CVD associated events. 
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SOLUBLE CD40 LIGAND: 
sCD40  ligand is one of the  signalling protein points to  both inflammatory and 
platelet interaction.   Increased levels of sCD40L   have reported to be 
correlated with an increased risk of cardiac events and it is expressed by 
activated platelets and increased plasma levels have been associated  with 
platelet activation. 
74
 
PREGNANCY ASSOCIATED PLASMA PROTEIN-A: 
PAPP-A is a  high molecular weight (- 200 kDa)  glycoprotein synthesized by 
the syncytiotrophoblast , a  zinc binding metalloproteinase  classified under 
matrix metalloproteinase (MMP)  which was formerly identified in the plasma 
of pregnant women. Elevated levels of PAPP-A  were found in  patients 
presenting with unstable plaque.  It is usually estimated during pregnancy in 
case of  screening for Down Syndrome. Human fibroblasts contains PAPP-A 
and released into circulation   during the disruption of  atherosclerotic plaque.  
Bayes-Genes et all demonstrated an increased PAPP-A concentrations in serum 
of patients with both unstable and acute coronary syndromes. 
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PAPP-A has also been evaluated as a marker of cardiovascular risk in 
symptomatic hyperlipidemic individuals showing a correlation with the degree 
of echogenicity of carotid atherosclerotic plaques.  
In a preliminary study,  PAPP-A showed  patterns are highly variable release  
ranging from 2 to 30 hours after the onset of chest pain. 
 
HEART FATTY ACID BINDING PROTEIN: 
H-FABP is a low molecular weight protein  (14-15)kDa which is very stable 
and abundant  made of -132 amino acids . It is a  soluble cytoplasmic protein of 
myocardial cells. It  is involved in the transport and metabolism of fatty acid 
and expressed mainly  in the myocardium. However ,  brain, kidney and skeletal 
muscle also have shown its minimal expression. Small size and water solubility 
facilitates rapid diffusion through the interstitial space and appears as eary as 90 
minutes after symptom onset and peaks within 6hours due to rapid renal 
clearance. 
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PLACENTAL GROWTH FACTOR (PIGF). 
It is a homodimeric glycoprotein, 46-56kDa in size, belongs to the vascular 
endothelial growth factor (VEGF) sub family. It exists in two isoforms PIGF-1 
and 2 . PIGF -2  has heparin binding domain and is a potent angiogenic factor. 
In patients with ACS, increased plasma levels of PIGF are associated with 
adverse cardiac outcomes during long-term follow up. This was emphasised as a 
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marker of vascular inflammation for risk stratification in patients with ACS 
rather than general markers of inflammation such as hs-CRP. 
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BRAIN NATRIURETIC PEPTIDE: 
It is a 32 amino acid polypeptide secreted by the ventricles of the heart in 
response to excessive stretching of   heart muscle cells. The release of BNP is 
modulated by calcium ions. The physiological actions  includes decreasing 
systemic vascular resistance and central venous pressure as well as increasing 
natriuresis. BNP is secreted along with a 76 amino acid N-terminal fragment 
that is biologically inactive. 
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ALBUMIN 
Albumin is a nonglycosylated low molecular weight globular protein of 585 
amino acids. It has a molecular weight of 66,438 Daltons. 60% of albumin is 
found in the extravascular space. HSA (Human Serum Albumin) is the most 
predominant protein in blood with multiple functions. It is produced in the liver. 
It has a half life of 19 days.  Analysed by X ray crystallography, it is found to be 
folded into three domains which are homologous. Its three dimensional 
structure has a heart shape which is stabilised by 17 intra chain disulfide bonds.  
The mean concentration of HSA is 0.63 mmol/L (40g/L).  Albumin Cobalt 
Binding (ACB) test is a recently reported biochemical test exploiting the 
property of normal serum albumin to bind transition metal cobalt. It was found 
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that albumin in the serum of patients with myocardial infarction showed 
reduced binding to cobalt. 
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PROPERTIES: 
 Albumin is relatively stable resisting denaturation than most of the 
plasma proteins. 
 Normal half life of albumin ranges from 15 – 19 days. 
 At pH of 8.6 albumin carries a net charge of about – 25 which accounts 
for its mobility towards anode. 
 One unpaired cysteine  in 34th position occurs partially in  exchangeable 
disulfide bonds with small compounds such as cysteine  and 
homocysteine. 
The metal binding property of HSA has been vastly researched on. It has 
been found that metallic ions bind to different sites on HSA. Extensive studies 
of HSA have revealed multiple  metal binding properties and the metal ions 
bind to a extensive range of sites. The binding comprising of the  amino acid 
sequence N-Asp-Ala-His-Lys  is very tyical. First three residues  have been 
shown to be necessary for metal ion binding whereas  the fourth residue 
(lysine)   not. These sites  have high affinity particularly for copper and nickel. 
The α-amino group, the δ-imidazole nitrogen from His3, the two intervening 
peptide nitrogen atoms, and the side-chain carboxyl group of Asp1 are 
specifically  involved in this binding property. 
 
63 
 
BINDING SITES:- 
 Site I binds salicylates, Sulfanomides 
 Site II – Tryptophan, thyroxine, octanoate 
 Imidizole of His 3- forms a binding site for cu++ ions 
N terminal- binds metal ions like cobalt, nickel, copper 
METABOLISM: 
Albumin is synthesized by the hepatic parenchymal cells except in fetal life, 
where yolk sac is the primary site. Catabolism occurs by pinocytosis by all 
tissue and the resulting free amino acids areutilized for synthesis of cellular 
proteins. Small amounts are also  lost into the gastro intestinal tract and the 
glomerular filtrate 
FUNCTIONS OF ALBUMIN: 
1.  Serves as a major component of colloid osmotic pressure inside the 
blood vessels. 
2. Transports  variety of  substances  including fatty acids , bilirubin , drugs 
calcium , metals etc... 
3. Serves as a storage form of amino acids which can be utilised in catabolic 
states. 
4.  Increases capillary permeability to small proteins by binding to 
endothelial membrane associated glycoprotein. 
5.   Albumin reduces the inflammatory response of platelets and neutrophils 
by inhibiting leukotrienes . 
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6.  It is essential for the metabolism and detoxification of  many 
compounds. 
7. Serves as an important component of protein buffer 
 
DECREASED PLASMA LEVELS:- 
1) Due to reduced synthesis as in liver disease . 
2) Increased loss  
- in urine in nephrotic syndrome. 
- Into intestine in protein losing enteropathy. 
- From the skin in burns. 
- In severe hemorrhage. 
3. Impaired uptake in malnutrition. 
4. Defective digestion or malabsorption. 
ANALBUMINEMIA:- 
It’s an inherited condition of plasma albumin with levels less than  0.5g/L43. 
REFERENCE LEVELS:- 
35 to 52 g/l or 3.5 to 5.2 g/dl. 
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ISCHEMIA MODIFIED ALBUMIN: 
 N-terminus  part of albumin  which is either damaged or replaced  by copper 
ion  is  termed as ischemia modified albumin (IMA) . Conditions necessary for 
altering the metal binding site of HSA are known to occur in vivo and probably 
occur within minutes  after the onset of myocardial ischemia. 
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 As a result of  hypoxia, acidosis, free-radical injury and energy-  dependent 
membrane disruption  which occurs during ischemia, the N-terminus of albumin  
is transformed   reducing    its binding capacity for metals.  Increasing 
concentration of IMA caused  less   cobalt binding therefore more residual 
unbound   cobalt   available to  complex with a chromogen  (dithiothreitol) the 
color of  which can be measured  photometrically. This is the basis of  the 
albumin cobalt-binding (ACB) test. An  increase in IMA is inversely related to 
the  unbound amount of cobalt, causing an increase  in coloured product 
produced in the  test platform. 
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  Saif Anwaruddin et al demonstrated  increased the sensitivity for 
detecting ischemia to 97%.with a negative predictive value of 92%. IMA  was 
highly when  combination of IMA–myoglobin–CK-MB–TnI estimations were 
done, which might improve the usefulness of standard biomarkers of 
myocardial ischemia.  They concluded that the results of IMA testing were 
additive to those of ECG and useful when used in  conjunction with markers of 
myocardial necrosis.
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   In another study done by Abdul-Fattah  et al they proved that Ischemia 
modified albumin is a very sensitive marker for the early diagnosis of myocardial 
ischemia before irreversible change like necrosis occur. 
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METHODS OF MEASUREMENT: 
 
 
Albumin Cobalt Binding Test 
ELISA  technique.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
MATERIALS AND METHODS: 
The study was conducted in Thanjavur Medical College Hospital.  50 patients 
with symptoms of acute coronary syndrome presented within 6 hours  of onset 
of pain in the causality  with  ECG findings correlated  and   were taken as 
subjects . 50 age and sex matched controls  were taken as control group.   
 INCLUSION CRITERIA:- 
1) Patients admitted with complaint of chest pain within 6 hours of onset. 
2) Electro cardio graphic findings showing abnormal ST-T wave changes (ST 
segment elevation or depression or deep symmetrical T wave inversion). 
EXCLUSION CRITERIA:- 
1)  Presence of renal diseases. 
2)  Presence of cirrhosis. 
3)  Presence of stroke, skeletal muscle injury, malignancy, trauma. 
4)   Critically ill patients. 
5)   Any  infectious diseases. 
6)   Serum albumin < 2 gms/dl , 
 7)   Serum creatinine > 3 mgs/dl. 
 
 
 
 
 
68 
 
BLOOD COLLECTION:- 
Informed consent was obtained for each patient and control prior to the study. 
5ml of blood samples were collected by vene puncture under strict  aseptic 
precaution as soon as the subjects got admitted as per the inclusion criteria. The 
samples were centrifuged and serum separated. One part of the sample was 
taken and analysis of CK-MB, LDH ,albumin  and creatinine were done 
immediately. Remaining part of the sample was stored for analysis of Ischemia 
Modified Albumin at  - 20º C. 12-14 hours fasting samples  were collected from 
all subjects during their hospital stay and analysis of total cholesterol, 
triacylglycerol and high density lipoprotein were done. 
ANALYSIS OF BLOOD SAMPLES: 
  The serum collected above was used for the estimation of the 
following parameters 
ESTIMATED PARAMETERS: 
1.  Ischemia Modified Albumin—Albumin Cobalt Binding test 
2. Serum  Creatine Kinase   -   Modified IFCC method 
3. Serum Lactate Dehydrogense  -  UV kinetic method 
4. Serum Aspartate Transaminase  -   Modified IFCC Method. 
5. Serum Urea    -   Urease method 
6. Serum   Creatinine  -  Modified  Jaffe,s  Method 
7. Serum  Albumin  -   Bromo Cresol Green colorimetric Method. 
8. Serum  glucose  -   Glucose oxidase – Peroxidase Method. 
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9. Total Cholesterol  -    Enzymatic  cholesterol esterase method 
10. Serum Triglycerides  -  GPO – PAP Method. 
11. Serum  High Density Lipoprotein  -   Phosphotungstic acid method. 
 
CALCULATED PARAMETERS: 
1.  Body Mass Index: (BMI):  weight in Kg 
           (height in meters)
2    
     
2. Very Low Density Lipoprotein  =  TGL/5 
3.  Low Density Lipoprotein  =  T- Chol – (LDL + VLDL)   
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ESTIMATION OF ISCHEMIA MODIFIED ALBUMIN: 
The tests were performed by chemical method using Cobalt chloride (hexa 
hydrate form) Dithiothreitol and Sodium chloride. 
PRINCIPLE :- 
Free Cobalt that does not bind to the Ischemia modified albumin in serum gives 
a brown coloured complex with Chromogen  dithiothreitol which is measured  
spectrophotometrically at 470 nm.Intensity of the colour is directly proportional 
to Ischemia modified albumin in serum. 
REAGENTS :- 
Cobalt chloride - 1 gm / litre 
Dithiothreitol - 1.5 gm / litre 
Sodium chloride - 9.0 gm / litre 
All reagents are freshly prepared. 
STANDARDIZATION OF THE PROCEDURE:- 
Preparation of standards - Cobalt chloride [CoCl2.6H2O] was used for 
preparation of cobalt standards. 
STOCK SOLUTION:- [1 gm % of cobalt] 
Dissolve 1.83 gms of cobalt chloride in deionised water and make up to 100ml. 
SUBSTOCK:- [10,000 μg/10 ml of cobalt] 
100 μl of stock solution is made up to 10ml. 
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WORKING STANDARDS:- 
Working standards of various concentrations were prepared from 
the sub stock solution as shown in table. 
Working standard 
Concentration   
(μg/dl) 
 
Stock solution 
(μl) 
 
Deionised 
water 
(μl) 
 
10 10 990 
40 40 960 
70 70 930 
100 100 900 
130 130 870 
Standards with Serial concentration were prepared as follows.  
 
 
 
 
REAGENTS:- 
1) COBALT CHLORIDE :- 
0.183 mgs of Cobalt chloride dissolved in 100ml of deionised water. 
2) DITHIOSTHREITOL [DTT]:- 
1.5 gm of Dithiothreitol dissolved in .1 litre of deionised water. 
3) 0.9 gms % SODIUM CHLORIDE:- 
9.0 grams of Sodium chloride dissolved in 1 litre of deionised  water to quench 
the reaction. 
 
CONC STD O.D BLANK STD - BLANK 
10 0.142 0.02 0.125 
40 0.345 0.02 0.325 
70 0.689 0.02 0.659 
100 0.904 0.02 0.874 
130 1.151 0.02 1.121 
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Procedure: 
 BLANK STANDARD TEST 
Sample -- -- 200µl 
Cobalt chloride 50 µl 50 µl 50 µl 
Deionised water 250 µl -- -- 
DTT -- 50 µl 50 µl 
NaCl 1ml 1ml 1ml 
 
Add 50μl of cobalt chloride to the serum sample, mix vigorously and after ten 
minutes of incubation add 50 μl of Dithiothreitol. Wait  for 2 minutes and then 
add 1ml of 0.9 % sodium chloride.  Read the absorbance at 470 nm after 1 
minute. 
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ABSORBANCE OF COBALT STANDARDS:- 
Reagent blank = 0.020 
CALCULATION:- 
Absorbance of unknown  x concentration of standard 
Absorbance of standard 
REFERENCE VALUES:- 
6 – 80units/ml. 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
0 20 40 60 80 100 120 140 
O
.D
 
std -blank 
cobalt  µg/dl 
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ESTIMATION OF SERUM (CK-MB) 
The tests are performed in reagent kit by Modified IFCC method. 
PRINCIPLE OF THE METHOD:- 
This procedure involves measurement of CK activity in the presence of an 
antibody to CK-M monomer. This antibody completely inhibits the activity of 
CK-MM and half of  the activity of CK-MB while not affecting the B subunit 
activity of CK-MB and CK-BB. Then the CK method is used to quantitatively 
determine CK-B activity. The CK-MB activity is obtained by multiplying the 
CK-B activity by two. 
        creatine kinase 
Creatine phosphate + ADP                          Creatine + ATP 
 
                hexokinase       
ATP + D-Glucose                                Glucose-6-phosphate +ADP 
 
 
    Glucose 6 Phospate dehydrogenase 
Glucose-6-phosphate + NADP 
+
                                 6 - Phospogluconate +   
                                                                                     + NADPH + H
+
  
REAGENTS:- 
REAGENT I:- (Buffer / Enzymes) 
REAGENT II:- (Polyclonal Antibody 
WORKING REAGENT:- 
Add 4ml of reagent I to one ml of reagent II. Mix gently by swirling  till 
completely dissolved. 
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PROCEDURE:- 
The reagent and sample are brought to room temperature 
 
To 1 ml of working reagent add 50 μl of sample and read immediately at 340 
nm 
NORMAL VALUES:- 
Serum: 0 – 24 u /L. 
 
 
 
 
 
 
 
 Blank Standard Test  
Reagent 1ml 1ml 1ml 
Distilled water 50 μL - - 
Standard - 50 μL - 
Sample - - 50 μL 
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ESIMATION OF LACTATE DEHYDROGENASE: (LDH) 
METHOD:   UV -  KINETIC METHOD. 
PRINCIPLE:  
Lactate Dehydrogenase catalyses the oxidation of lactate to pyruvate 
accompanied by  simultaneous reduction of NAD to NADH. LDH activity is 
proportional to the increase in absorbance  due to the reduction of NAD. 
       LDH 
Lactate   + NAD                        pyruvate  +  NADH 
 
REAGENTS: 
REAGENT 1: 
NAD   :5mmol/L 
Lactate   :50 mmol/L 
REAGENT 2: 
Buffer  (pH 9.3 at 25 ºC)  100 mmol/L 
WORKING REAGENT PREPARATION:  (For 10 x 1.1 ml) 
  one tablet of 1 LDH  was reconstituted  with 1.1 ml of 2LDH .   Mixed gently 
to dissolve the contents and used after 5 minutes. 
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PROCEDURE: 
Pipette  1ml of working reagent with 50 µl of sample , mix and read the first 
absobance at one minute  and at 30, 60, 90 seconds at 340nm.  The mean 
change in the absorbance per minute was calculated as enzyme activity. 
NORMAL RANGE:  114  - 240 IU/L 
ESIMATION OF   ASPARTATE TRANSAMINASE: (AST) 
METHOD:   MODIFIED IFCC METHOD 
PRINCIPLE:   Aspartate transaminase (AST)   catalyses the transfer of amino 
group from L-aspartate  to α –ketoglutarate to yield oxaloacetate and L- 
glutamate. The oxaloacetate undergoes reduction with simultaneous oxidation 
of NADH to NAD in the malate dehydrogenase catalysed  indicator reaction.  
The resulting rate of decrease in absorbance at 340nm is directly proportional to 
the AST activity. 
                                                                                                  Aspartate  
                                                                                                 transaminase 
L – Aspartate +   α –ketoglutarate                      oxaloacetate  +  L-gutamate 
                                                                                    malate  
                                                                             dehydrogenase 
Oxaloacetate   +  NADH + H+                       Malate + NAD+ 
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REAGENT:1 
 Tris nuffer  (pH 7.8)   20mmol/L 
L-Aspartate     230mmol/L 
LDH      >33.3µkat/L 
2-Oxaloacetate    13.21mmol/L 
MDH      >33.3µkat/L 
REAGENT: 2 
NADH     1.51 mmol/L 
REAGENT PREPARATION: 
Working reagent was prepared by mixing 4 parts of R1 with 1 part of R2 per 
assay tube. 
 PROCEDURE:   
500 µl of working reagent was mixed with 25µl of sample , mixed well and 
aspirated. 
CALCULATION: 
SGOT (AST)  activity (IU/L)  =  DA/ min x factor (3376) 
NORMAL RANGE:   10 – 40 U/L 
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ESTIMATION OF GLUCOSE: 
METHOD: GLUCOSE OXIDASE PEROXIDASE METHOD. 
PRINCIPLE: 
Glucose in the sample is oxidised  to gluconic acid and hydrogen peroxide by 
glucose oxidase. The enzyme peroxidise catalyses oxidative coupling of 4- 
aminophenozone with phenol to give pink coloured quinoe -imine complex. The 
intensity of the colour is proportional to the concentration of  glucose present in 
the sample. 
                                                       Glucose oxidase 
Glucose + O2 +H2O                          Gluconic acid  + Hydrogen peroxide. 
 
                                                         peroxidise 
H2O2 + Phenol  + 4 AAP                       Quinoeimine dye + H2O 
 
Glucose standard: 100mg/dl 
Specimen:  fresh  unhemolysed serum . 
ASSAY PROCEDURE: 
Enzyme reagent 1ml 1ml 1ml 
Blank 10 µl   
Standard - 10 µl - 
Test - - 10 µl 
 Mixed well after each addition and incubated at 37ºC for 5 mts. The absorbance 
of the Standard and the test were read against reagent blank at 505nm. 
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Calculation: 
Glucose (mg/dl) = Absorbance of test × Concentration of standard (mg/dl) 
                          Absorbance of standard 
Glucose Standard: 100mg/dl 
Linearity:  Upto 500mg/dl  
Normal Values: Glucose fasting: 65-100mg/dl 
                           Glucose postprandial: 90-140mg/dl 
QUANTITATIVE DETERMINATION OF ALBUMIN:- 
(BCG DYE BINDING METHOD):- 
PRINCIPLE OF THE METHOD:- 
Albumin in a buffered solution reacts with the anionic bromo cresol 
green (BCG) with a dye binding reaction to give a proportionate 
green colour which is measured at 630 nm (600 – 650 nm). 
REAGENTS:- 
Reagent I - Bromocresol green 
                  Succinic acid - 94 m mol /L 
                  Sodium hydroxide - 10.2 m mol /L 
                  BCG :- 0.149 m mol /L. 
PROCEDURE:- 
The samples and the reagent were brought to room temperature    before use. 
Add 1 ml of reagent to 10 μl of sample, mix incubate for 1 minute  at room 
temperature, and read at 630 nm. 
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 Blank Standard Test 
Reagent 1ml 1ml 1ml 
Standard -- 10 μL  
Sample -- -- -- 10 Μl 
Standard Concentration: 6gm/dl 
Albumin  (gm/dl) = Absorbance of test × Concentration of standard (mg/dl) 
                          Absorbance of standard 
Normal values = 3.5 – 5 g / dl. 
ESTIMATION OF BLOOD UREA: 
METHOD:  UREASE – GLDH METHOD 
PRINCIPLE: 
Urea is hydrolyzed  to ammonia and carbon dioxide by Urease. Then Glutamate 
dehydrogenase (GLDH) converts ammonia and α Keto glutarate to glutamate 
and water with the concurrent oxidation of reduced NADH to NAD
+ 
. Two 
moles of NADH are oxidized for each mole of urea present. 
Urea + H2O 
      
      2NH4+ + co2 . 
NH4
+
 + NADH + H
+
 + 2-oxoglutarate 
    
     Glutamate + NAD+. 
The initial rate of decrease in absorbance at 340nm is proportional to the urea 
concentration in the sample. 
Reagent composition: 
Reagent 1: 
 α-Keto glutaric acid 99.8mmol/L 
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Urease 23.5ku/L, GLDH 3.5ku/L, Adenosine diphosphate 
7.6mmol/L, Sodium Acid 0.2%. 
Reagent 2:  NADH 2.95mmol/L, sodium Acid 0.1% urea standard 
50mg/dl. 
Reagent Preparation: 
 Working reagent was prepared by mixing 4 parts of reagent 1 
with one part of reagent 2. 
Procedure: 3 test  tube were labeled as Blank, standard and test and the 
procedure is done as follows: 
Tubes 
Working 
reagent 
Standard Test sample 
Distilled 
water 
Blank 1000µl - - 10µl 
Standard 1000µl 10µl - - 
Test 1000µl - 10µl - 
The tubes were mixed well and the absorbance was read after 20 seconds (A1) 
and 60 sec (A2) at 340nm. 
Calculation: 
∆A = A2 – A1. 
                             ∆A of test           
Urea in mg/dl =                           × Concentration of standard (50mg/dl). 
                        ∆A of standard 
Linearity:    The method is linear upto 200mg/dl. 
Reference Interval:  15-30mg/dl. 
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ESTIMATION OF SERUM CREATININE 
Method:    Modified Jaffe’s Method. 
          Principle: Creatinine reacts with alkaline picrate to produce an orange-yellow 
colour. The intensity of the colour is directly proportional to the 
concentration of Creatinine and is measured photometrically at 510nm. 
Reagent Composition:  
Reagent No Composition Concentration 
1 Picric acid 25.8mmol/L 
2 Sodium hydroxide 95mmol/L 
Concentration of standard creatinine 2 mg/dl 
Reagent Preparation 
 Equal Volumes of reagent 1 and reagent 2 were mixed and 
waited for 15 minutes before use. 
Procedure: 3 test tubes were taken and labeled as Blank, Standard and test and 
the procedure was done as follows: 
Tubes 
Working 
reagent 
Standard Test sample 
Distilled 
water 
Blank 1000µl - - 100µl 
Standard 1000µl 100µl - - 
Test 1000µl - 100µl - 
 
84 
 
 The tubes were mixed well and the absorbance was read after 
20 seconds (A1) and 80 sec (A2) at 510nm, against reagent blank with distilled 
water. 
Calculation:  ∆A= A2 – A1.                           
Serum Creatinine (mg/dl) =  ∆A of test     ×  Concentration of standard  
                                          ∆A of standard                  
Linearity: This assay is linear upto 20mg/dl. 
Reference Range: Males:   0.7-1.4 mg/dl 
   Females:   0.6-1.2mg/dl.  
ESTIMATION OF TOTAL CHOLESTEROL: 
Method:  Cholestrol Oxidase – PAP method, End Point Analysis. 
Principle: 
1.Cholestrol Ester + Water 
        
        Cholestrol + fatty acid             
2.Cholesterol + oxygen 
                  
                 Cholest – 4- en-3 one + H2O2 
3. 2H2O2 +  4AAP + Phenol
           
          Quinoneimine dye + 4 H2O 
  4AAP - 4 Amino antipyrine 
           Absorbance of quinoneimine is directly proportional to cholesterol 
concentration. 
Reagent composition: 
Goods buffer (PH 6.4) : 100mmol/L 
Cholesterol Oxidase : >100U/L 
Cholesterol Esterase : >200U/L 
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Peroxidase        : >3000 U/L 
4- Amino anti pyrine : 0.3mmol/L 
Phenol   : 5mmol/L 
Procedure: 
Reagents Blank Standard Sample 
Working reagent 1000µl 1000µl 1000µl 
Distilled water 10µl - - 
Standard - 10µl - 
Sample - - 10µl 
The tube were mixed well and incubated for 10min at room temperature. The 
absorbance of the test and standard were read against reagent blank at 505nm. 
Calculation: 
Cholesterol in mg/dl = ∆A of test × Concentration of standard (mg/dl). 
                                 ∆A of standard 
Concentration of cholesterol standard 200mg/dl. 
Reference Range 
AGE  SERUM CHOLESTEROL(mg/dl) 
2-12 months 60-190 
≥1year 110-230 
Adults <200 
 
Linearity:  This method is linear upto 700mg/dl 
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ESTIMATION OF TRIGLYCERIDES 
Method: Enzymatic method with glycerol Phosphate oxidase (GPO – PAP 
method) 
Principle: 
Triglycerides + H2O 
      
      Glycerol + free fatty acids                 
           Glycerol + ATP 
               
    
             Glycerol 3 Phosphate + ADP 
           Glycerol 3 Phosphate + O2 
   
    DAP + H2O2 
 ATP – Adenosine Triphosphate, 4 AAP 4 Amino Antipyrine,  
DHBS—3,5 Dichloro 2-Hydroxy Benzene Sulfonate 
The Intensity of the Quinoneimine dye formed is proportional to the 
Triglyceride concentration in the sample when measured at 540nm. 
Reagent Composition: 
Reagent 1 (Enzymes/Chromogen): 
Lipoprotein lipase 4000U/L 
4-Amino Antipyrine 0.4 mmol/L 
ATP 2 mmol/L 
Glycerol Kinase 1500U/L 
Peroxidase 2200U/L 
Glycerol Phosphate 
Oxidase 
4000U/L 
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Reagent – 2: 
Pipes buffer pH7.0: 40mmol/L 
DHBS : 0.2 mmol/L 
Magnesium salt: 2.5 mmol/L 
Working Reagent Preparation: 
 The working reagent was prepared by mixing 4 parts of R1 with 1 part of 
R2, and is stable for 90 days at 2-8
0
C. 
Procedure: 
 Three test tubes were taken and labeled as Blank (B), Test (T) and 
Standard (S). The procedure was as follows: 
Reagents Blank Standard Sample 
Working reagent 1000µl 1000µl 1000µl 
Distilled water 10µl - - 
Standard - 10µl - 
Sample -  10µl 
The tubes were mixed and incubated for 10 minutes. Absorbance was read at 
540nm for standard and sample against reagent blank. 
Calculation: 
Triglycerides (mg/dl) = Absorbance of test × concentration of standard (mg/dl) 
                                   Absorbance of standard  
Reference Values:  25-160mg/dl 
Linearity: Upto 1000mg/dl 
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HDL CHOLESTEROL ESTIMATION 
Method: Phosphotungstic acid / Magnesium Precipitation method. 
Principle: 
 Chycomicrons, VLDL-C and LDL-C are precipitated from the serum by 
phosphotungstate in the presence of divalent cations such as Magnesium. The 
HDL cholesterol remains unaffected in the supernatant and is estimated using 
cholesterol reagent 
Serum  
              
                HDL-C    +    {LDL-C+VLDL–C+ Chylomiorons} 
                                   (Supernatant)     ( Precipitate) 
 
Reagent Composition: 
Precipitating reagent: 
                                                                                                                
 
 
HDL Cholesterol standard 25mg/dl. 
Precipitation: 
 Precipitation of LDL-C, VLDL-C and chylomicrons were done by adding 
500µl of precipitating reagent into 250µl of serum. The tube was mixed well 
and allowed to stand for 10 min. Then it was centrifuged at 3000 rpm for 10 
min and a clear supernatant was obtained. The supernatant was used to 
determine the concentration of HDL cholesterol in the sample. 
 
Phosphotungstic acid 2.4 mmol/L 
Magnesium Chloride 40 mmol/L 
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Procedure: 
Reagents Blank Standard Sample 
Cholesterol working 
reagent 
1000µl 1000µl 1000µl 
Distilled water 50µl - - 
Standard - 50µl - 
Supernatant - - 50µl 
Tubes were mixed well and incubated for 10min at room temperature. The 
absorbance of the standard and the test samples were read at 505nm against 
reagent blank. 
Calculation: 
HDL Cholesterol (mg/dl) = Absorbance of test × concentration of standard ×dilution factor.                
                                    Absorbance of standard 
                       
                          =   Absorbance of test × 25 × 3 
          Absorbance of standard 
Linearity: Upto 125mg/dl 
Normal Values:Males: 30-65mg/dl 
                         Females: 35-80 mg/dl. 
CALCULATED PARAMETERS:- 
FRIEDWALD’S FORMULA: 
VERY LOW DENSITY LIPOPROTEIN: Triacylglycerol 
                                                                             5 
LOW DENSITY LIPOPROTEIN:  
Total Cholesterol – HDL – Triacylglycerol 
5 
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                  MASTER CHART – I (CONTROL  GROUP) 
91 
 
 
S.NO 
 
Age 
(Yrs) 
sex 
Wt 
(Kg) 
Ht 
(mts) 
BMI 
(kg/m
2
) 
SBP 
(mm 
Hg) 
DBP 
(mm 
Hg) 
IMA 
(U/dl) 
S.ALB 
(g/dl) 
CKMB 
(U/L) 
RBS 
(mg/dl) 
UREA 
(mg/dl) 
CREAT 
(mg/dl) 
T-CHOL 
(mg/dl) 
TGL 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
LDH 
(U/L) 
SGOT 
(U/L) 
1 54 M 74 1.5 32.88 130 86 24.6 3.5 12 110 25 0.8 146 120 38 84 24 54 21 
2 51 M 54 1.58 21.63 136 80 24 3.6 9.45 120 24 0.7 148 141 35 84.8 28.2 85 28 
3 54 M 74 1.65 27.1 124 84 22.6 3.8 8.62 110 28 0.9 175 152 34 110.6 30.4 86 24 
4 61 M 63 1.58 25.23 136 80 58.75 3.86 14.2 115 22 1.2 146 110 40 84 22 110 25 
5 58 M 80 1.59 31.64 138 70 22.6 3.84 12.5 114 24 0.9 165 94 52 94.2 18.8 110 28 
6 54 M 62 1.63 23.33 142 74 60 3.8 11.3 117 27 0.6 164 85 42 105 17 121 26 
7 49 M 81 1.68 28.69 140 76 52.2 3.9 14.2 102 25 0.8 154 152 40 83.6 30.4 142 23 
8 57 M 45 1.45 21.40 140 78 10.6 4.1 12.2 105 24 0.75 158 121 44 89.8 24.2 110 35 
9 48 M 49 1.56 20.13 130 70 18.6 3.89 11.3 114 26 0.85 175 142 39 107.6 28.4 151 26 
1 49 M 58 1.89 16.23 130 80 12.32 3.6 10 109 25 0.95 148 132 45 76.6 26.4 125 38 
11 61 M 85 1.65 31.2 120 82 61.24 3.8 10.2 107 24 0.87 126 123 42 59.4 24.6 132 31 
12 60 M 68 1.64 25.28 122 84 57.64 4.2 10.5 116 19 0.86 124 123 32 67.4 24.6 156 35 
13 54 M 67 1.54 28.25 132 80 24.32 3.6 11.2 108 26 0.85 142 133 35 80.4 26.6 165 24 
14 58 M 81 1.58 32.44 130 80 42.2 4.12 10.6 124 28 0.96 152 142 36 87.6 28.4 164 25 
15 52 M 82 1.57 33.26 130 80 24.65 4.3 10.6 113 31 0.76 124 147 42 52.6 29.4 154 26 
16 53 M 59 1.68 20.9 120 78 25.46 3.8 12.9 115 21 0.64 152 154 34 87.2 30.8 154 35 
17 54 M 69 1.52 29.86 110 70 48.56 3.9 14.2 109 31 0.75 162 121 24 113.8 24.2 168 38 
18 58 M 65 1.69 22.75 120 90 52.6 3.8 16.6 122 30 0.65 165 132 45 93.6 26.4 110 24 
19 54 M 67 1.64 24.91 120 84 36.98 3.4 14.2 121 19 0.85 168 151 38 99.8 30.2 123 35 
20 49 M 68 1.69 23.80 130 80 24.6 3.6 16.2 108 32 0.46 142 141 44 69.8 28.2 123 31 
21 51 M 64 1.69 22.40 110 80 28.6 3.54 12.4 105 32 0.65 175 156 41 102.8 31.2 132 21 
22 52 M 69 1.66 25.03 120 84 24.26 4.12 1.5 104 32 0.9 157 121 42 90.8 24.2 147 33 
23 57 M 68 1.65 24.97 128 82 45.26 4.5 10.3 122 22 0.8 142 128 42 74.4 25.6 154 24 
24 55 M 82 1.64 30.4 124 78 54.69 3.8 12.2 123 24 0.6 132 124 47 60.2 24.8 124 26 
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S.NO 
 
Age 
(Yrs) 
sex 
Wt 
(Kg) 
Ht 
(mts) 
BMI 
(kg/m
2
) 
SBP 
(mm 
Hg) 
DBP 
(mm 
Hg) 
IMA 
(U/dl) 
S.ALB 
(g/dl) 
CKMB 
(U/L) 
RBS 
(mg/dl) 
UREA 
(mg/dl) 
CREAT 
(mg/dl) 
T-CHOL 
(mg/dl) 
TGL 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
LDH 
(U/L) 
SGOT 
(U/L) 
25 54 M 80 1.49 36.03 120 80 58.64 3.9 14.2 128 25 0.7 132 134 48 57.2 26.8 110 23 
26 49 M 80 1.56 32.87 130 80 44.36 3.6 14.5 114 24 0.68 136 132 39 70.6 26.4 100 33 
27 45 M 74 1.49 33.33 130 80 44.26 3.4 13.2 117 21 0.78 163 143 42 92.4 28.6 98 12 
28 51 M 75 1.56 30.81 120 80 28.64 3.6 15.2 105 22 0.74 153 152 39 83.6 30.4 85 16 
29 48 M 74 1.59 29.27 124 82 26.84 3.5 12.6 115 28 0.97 135 142 35 71.6 28.4 95 25 
30 52 M 75 1.69 26.25 126 82 58.64 3.65 16.5 116 26 0.94 163 134 36 100.2 26.8 94 18 
31 43 M 74 1.57 30.0 132 82 54.24 3.6 14.3 112 24 0.68 154 125 45 84 25 96 19 
32 54 M 76 1.68 26.92 130 80 26.54 3.8 16.2 117 18 0.95 185 124 36 124.2 24.8 98 26 
33 52 M 85 1.68 30.11 140 80 25.56 3.7 12.6 98 19 1 13 124 45 -56.8 24.8 84 24 
34 51 M 59 1.49 26.57 130 84 42.2 3.4 20.12 94 25 1 135 127 42 67.6 25.4 74 22 
35 58 M 68 1.47 31.46 126 82 28.45 3.8 10.2 110 26 0.9 145 126 41 78.8 25.2 56 21 
36 46 M 65 1.49 29.27 130 84 45.26 3.9 12.2 95 24 0.75 148 152 40 77.6 30.4 15 27 
37 49 F 65 1.59 25.71 130 82 42.8 3.6 10.2 98 22 0.68 147 123 40 82.4 24.6 18 28 
38 43 F 69 1.57 27.99 126 80 28.62 3.4 14.6 110 21 0.95 184 142 45 110.6 28.4 99 26 
39 45 F 65 1.68 23.03 130 78 26.8 3.6 10.6 112 23 0.74 151 125 46 80 25 110 24 
40 48 F 65 1.56 26.7 136 80 48.8 3.8 8.6 120 28 0.78 141 126 48 67.8 25.2 86 22 
41 52 F 81 1.68 28.69 126 80 56.6 3.7 13.2 124 24 0.85 154 126 43 85.8 25.2 84 24 
42 46 F 80 1.67 28.68 130 70 54.62 4.1 12.8 110 27 0.82 165 128 40 99.4 25.6 79 23 
43 49 F 74 1.68 26.21 130 84 19.84 3.6 11 100 19 0.95 156 126 45 85.8 25.2 103 26 
44 47 F 75 1.68 26.57 136 80 52.6 3.8 10.8 96 26 0.84 145 124 39 81.2 24.8 98 28 
45 45 F 72 1.56 29.5 120 82 26.64 3.6 15.2 95 24 0.85 154 124 38 91.2 24.8 112 24 
46 52 F 73 1.69 25.55 110 78 54.2 4.2 12.5 94 31 1 175 125 45 105 25 87 16 
47 51 F 82 1.7 28.37 122 70 29.98 4.1 11.8 110 25 0.87 157 145 42 86 29 141 21 
48 54 F 71 1.64 26.39 110 80 24.28 4.2 12.2 121 34 0.84 147 168 42 71.4 33.6 68 19 
49 51 F 60 1.65 22.03 130 78 24.64 3.6 10.6 110 25 0.85 185 165 41 111 33 92 18 
50 56 F 72 1.56 29.5 110 80 48.98 4.1 14.8 106 31 0.98 131 166 40 57.8 33.2 120 25 
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                          MASTER CHART-II (STUDY GROUP) 
 
 
 
 
s.no 
Age 
(yrs) 
sex 
Wt 
(kg) 
Ht 
(mts) 
BMI 
(kg/m2) 
SBP 
(mm 
Hg) 
DBP 
(mm 
Hg) 
Duration 
(hours) 
IMA 
(U/dl) 
S.ALB 
(g/dl) 
 
CKMB 
(U/L) 
RBS 
(mg/dl) 
UREA 
(mg/dl) 
CREAT 
(mg/dl) 
 
T-CHOL 
(mg/dl) 
TGL 
(mg/dl) 
HDL 
(mg/dl) 
VLDL 
(mg/dl) 
LDL 
(mg/dl) 
LDH 
(mg/dl) 
SGOT 
(U/L) 
1 46 M 85 1.59 33.62 142 92 3 118 3.84 22.2 150 32 0.6 240 174 28 4.44 212 145 28 
2 49 M 84 1.63 31.61 140 84 5 122.2 3.8 84.2 204 34 0.8 260 145 56 16.84 204 142 28 
3 47 M 79 1.68 27.99 150 92 4 112 3.9 69.5 140 25 0.75 280 185 54 13.9 226 156 39 
4 45 M 92 1.45 43.75 158 82 3 104.2 4.1 20.6 150 26 0.85 240 203 28 4.12 212 152 32 
5 52 M 85 1.56 34.92 162 80 6 184 3.89 124 210 24 0.95 198 205 32 24.8 166 121 56 
6 51 M 74 1.89 20.71 164 90 3 98.24 3.6 24 120 28 0.87 164 152 34 4.8 130 110 36 
7 54 M 72 1.65 26.44 164 92 3 102.65 3.8 18.2 110 29 0.86 194 126 36 3.64 158 135 36 
8 51 M 98 1.64 36.43 162 94 4 125 4.2 102.2 142 31 0.85 240 152 34 20.44 206 142 36 
9 56 M 92 1.54 38.79 170 92 3 104.25 3.6 24.02 250 35 0.96 168 112 28 4.804 140 142 32 
10 54 M 93 1.58 37.25 156 92 6 125 4.12 84 184 32 0.76 224 125 28 16.8 196 124 59 
11 58 M 85 1.57 34.48 150 82 3 99.25 4.3 20.25 210 26 0.64 184 124 27 4.05 157 121 32 
12 52 M 82 1.68 29.05 180 100 7 122.25 3.8 100.4 175 28 0.75 220 126 29 20.08 191 162 84 
13 53 M 74 1.52 32.02 160 100 4 106.65 3.9 56.62 182 31 0.65 224 132 31 11.324 193 142 51 
14 54 M 69 1.69 24.15 190 110 6 140 3.8 98.24 184 24 0.85 264 210 29 19.648 235 152 86 
15 58 M 68 1.56 27.94 170 110 4 112.24 3.6 69.66 142 37 0.46 168 112 34 13.932 134 142 53 
16 54 M 72 1.68 25.5 140 100 6 124.25 4.12 98.35 152 24 0.8 148 123 25 19.67 123 162 69 
17 49 M 68 1.67 24.38 142 90 3 119.5 4.3 20.24 110 25 0.7 174 142 45 4.048 129 148 39 
18 51 M 61 1.68 21.61 138 92 3 123.25 3.8 19.25 146 35 0.9 224 124 48 3.85 176 146 41 
19 52 M 65 1.68 23.03 148 90 5 108.45 3.9 62.24 140 26 1.2 264 152 26 12.448 238 162 59 
20 46 M 71 1.56 29.17 154 86 6 128.26 3.8 99.25 120 38 0.9 256 152 47 19.85 209 154 86 
21 49 M 82 1.69 28.71 140 100 6 126.56 3.4 92.84 108 36 0.6 158 156 26 18.568 132 156 85 
22 43 M 65 1.7 22.49 150 120 4 106.24 3.6 75.28 124 29 0.8 185 158 28 15.056 157 162 72 
23 45 M 68 1.64 25.28 140 110 6 142.24 3.54 124.4 120 35 0.75 174 148 42 24.88 132 152 84 
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s.no 
Age 
(yrs) 
sex 
Wt 
(kg) 
Ht 
(mts) 
BMI 
(kg/m2) 
SBP 
(mm 
Hg) 
DBP 
(mm 
Hg) 
Duration 
(hours) 
IMA 
(U/dl) 
S.ALB 
(g/dl) 
 
CKMB 
(U/L) 
RBS 
(mg/dl) 
UREA 
(mg/dl) 
CREAT 
(mg/dl) 
 
T-CHOL 
(mg/dl) 
TGL 
(mg/dl) 
HDL 
(mg/dl) 
VLDL 
(mg/dl) 
LDL 
(mg/dl) 
LDH 
(mg/dl) 
SGOT 
(U/L) 
24 48 M 73 1.65 26.81 150 110 4 121.98 4.12 84.24 98 26 0.85 210 127 41 16.848 169 148 54 
25 52 M 91 1.69 31.86 160 100 6 154.24 4.5 94.24 90 35 0.65 213 124 51 18.848 162 142 98 
26 46 M 92 1.69 32.21 140 92 4 124 3.8 84.46 110 28 0.9 158 131 48 16.892 110 117 28 
27 52 M 56 1.66 20.32 130 90 6 130.36 3.6 104.25 98 27 0.8 178 151 39 20.85 139 152 84 
28 53 M 59 1.65 21.67 150 90 3 96.24 3.8 20.24 148 24 0.6 179 141 42 4.048 137 126 38 
29 54 M 75 1.64 27.88 140 100 4 98.42 3.7 64.24 94 25 0.7 217 173 45 12.848 172 142 65 
30 58 M 59 1.49 26.57 170 110 5 89.64 3.4 74.42 106 29 0.68 198 112 46 14.884 152 152 69 
31 54 M 64 1.56 26.29 140 100 6 108.62 3.8 86.24 164 36 0.78 168 124 25 17.248 143 142 95 
32 49 M 85 1.49 38.28 150 92 3 101.24 3.9 24 184 35 0.74 214 123 28 4.8 186 136 35 
33 51 M 71 1.56 29.17 158 94 4 120.24 3.6 82.52 142 34 0.97 218 154 29 16.504 189 156 68 
34 52 M 75 1.59 29.66 146 92 6 126.24 4.02 88.24 150 38 0.94 234 145 31 17.648 203 128 94 
35 51 M 76 1.69 26.60 150 94 4 98.84 4.12 82.42 142 37 0.85 214 126 35 16.484 179 127 96 
36 52 M 81 1.57 32.86 140 92 3 106.64 4.5 26.2 132 39 0.46 200 154 31 5.24 169 145 36 
37 57 F 71 1.68 25.15 120 90 3 108.24 3.8 16.68 162 25 0.65 196 146 32 3.336 164 125 38 
38 55 F 84 1.68 29.76 130 90 6 126 3.9 92.84 142 29 0.9 175 142 34 18.568 141 126 94 
39 54 F 82 1.47 37.94 150 100 4 106.24 3.6 84.26 124 28 0.8 185 148 26 16.852 159 142 78 
40 49 F 59 1.49 26.57 130 90 4 99.5 3.4 64.42 157 27 0.6 201 122 31 12.884 170 152 84 
41 45 F 58 1.59 22.94 140 90 6 120.54 3.6 86.74 126 32 0.7 205 119 32 17.348 173 121 90 
42 51 F 57 1.57 23.12 130 90 4 96.52 3.5 79.98 146 31 0.68 165 129 28 15.996 137 120 59 
43 48 F 61 1.68 21.61 132 90 4 96.66 3.65 84.28 110 34 0.78 178 131 29 16.856 149 142 68 
44 52 F 62 1.56 25.47 160 100 3 104.24 3.6 22.46 152 26 0.74 182 124 29 4.492 153 124 38 
45 43 F 66 1.68 23.38 126 84 4 100.23 3.8 81.12 110 24 0.78 162 125 34 16.224 128 132 56 
46 49 F 68 1.67 24.38 140 90 4 98.28 3.6 74.54 140 32 0.85 149 153 34 14.908 115 122 67 
47 57 F 82 1.68 29.05 150 90 3 100.48 3.4 24.32 120 26 0.82 199 160 32 4.864 167 126 35 
48 48 F 69 1.68 24.44 140 90 4 97.58 3.6 74.56 126 21 0.95 156 140 34 14.912 122 127 68 
49 49 F 61 1.56 25.06 130 90 7 125.6 3.5 84.84 124 24 0.84 154 151 35 16.968 119 142 79 
50 61 F 68 1.69 23.80 142 94 6 142 3.65 96.8 142 28 0.85 176 168 36 19.36 140 135 95 
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RESULTS AND STATISTICS: 
 
In this study 50 patients were enrolled over an eleven months period from 94 
eligible patients. The majority of the patients were male (74%) and the mean 
age was  51.13yrs . The mean age for females was 51.28yrs.  The overall 
characteristics of the study group including the risk factors, biological variation 
etc are listed in table I. Among the data available on admission in the 
emergency department, factors associated with ACS were age , hyperlipidemia, 
smoking, hypertension. Positive family history and BMI.  
  CHARACTERISTICS OF THE STUDY POPULATION (TABLE I) 
VARIABLE ACS (NUMBER) PERCENTAGE 
Male 37 74% 
Diabetes 19 38% 
Hyperlipidemia 24 48% 
Smokers 27 54% 
Hypertension 35 70% 
Family history 20 40% 
BMI >25kg/m
2
 35 70% 
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                                                AGE DISTRIBUTION (Table II) 
 
AGE CONTROL  
(n=50) 
STUDY 
(n = 50) 
TOTAL 
(n = 100) 
41-50yrs 17 34% 19 38% 36 36% 
51-60 yrs 31 62% 30 60% 61 61% 
> 60 yrs 2 4% 1 2% 3 3% 
                                          Age Distribution (Fig 1) 
 
Table II shows the age distribution between control and study groups. The mean 
age falls between 51.88 ±4.51. All the patients included in the study were 
divided in three categories . 
Group I 41 -50yrs    17  34% 
Group II – 51 -60 yrs  31  62% 
Group III  -  >  60yrs   2  4% 
34 % 
62% 
4% 
38% 
60% 
2% 
40 - 50  50 - 60 >60 
control study 
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                                          GENDER DISTRIBUTION (Table III) 
 
 CONTROL  
(n=50) 
STUDY 
(n = 50) 
TOTAL 
(n = 100) 
Male 37 74% 37 74% 74 74% 
Female 13 26% 13 26% 26 26% 
 
 Gender distribution (both control and study) [Fig 2] 
 
 
 
Table III shows gender distribution in both control and study group. Among the 
patients taken in this study  74% were male 
 
 
 
 
 
74% 
26% 
Gender distribution  
male female 
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BODY MASS INDEX (Table IV) 
BMI Category Control   
 (n=50) 
Cases  
(n=50) 
<18.5 Underweight 1 0 
18.5 -24.9 Normal  12 15 
25 - 29.9 Over weight 24 21 
30-34.9 Obesity Gr 1 12 8 
35- 39.99 Obesity Gr 2 1 6 
 
 
 Mean Standard 
deviation 
Mean 
Rank 
Sum of 
Ranks 
Mann 
Whitney U 
score 
Statistical 
Significance 
Case 28.25 5.39 51.49 2475.5 1200.5 0.735 
Control 27.24 4.03 49.51 2574.5 
 
BAR DIAGRAM:I 
 
Table IV  shows the distribution of BMI in the study group. 
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DESCRIPTIVE STATISTICS   OF CONTROL 
GROUP (Table VI) 
 Number Minimum Maximum Mean Std. Deviation 
AGE 50 43.00 61 51.88 4.51 
WT 50 45.00 85 70.46 9.01 
HT 50 1.450 1.89 1.61 0.08 
BMI 50 16.23 36.03 27.24 4.02 
SBP 50 110.0 142 126.92 8.19 
DBP 50 70.00 90 79.76 4.17 
IMA 50 10.60 61.24 37.60 14.74 
S.ALBUMIN 50 3.400 4.5 3.79 0.26 
CKMB 50 1.500 20.12 12.40 2.79 
RBS 50 94.0 128 110.8 8.68 
UREA 50 18.00 34 25.26 3.86 
CREAT 50 .4600 1.2 0.82 0.13 
T-CHOL 50 13.00 185 149.92 25.07 
TGL 50 85.00 168 133.46 16.34 
HDL 50 24.00 52 40.70 4.78 
LDL 50 56.80 124.2 82.53 25.82 
VLDL 50 17.00 33.6 26.69 3.27 
LDH 50 15.00 168 108.04 34.28 
SGOT 50 12.00 38 25.44 5.68 
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DESCRIPTIVE STATISTICS OF STUDY GROUP (Table VII) 
 N Minimum Maximum Mean Std. Deviation 
AGE 50 43 61 51.18 4.09 
WT 50 56 98 73.78 11.07 
HT 50 1.45 1.89 1.62 .08 
BMI 50 20.32 43.75 28.25 5.38 
SBP 50 120 190 148.28 14.26 
DBP 50 80 120 94.28 8.21 
DURATION 50 3 7 4.46 1.28 
IMA 50 89.64 184 115.07 17.55 
S.ALBUMIN 50 3.40 4.5 3.80 .27 
CKMB 50 16.68 124.4 67.87 31.85 
RBS 50 90 250 142.24 33.28 
UREA 50 21 39 29.80 4.75 
CREAT 50 .46 1.2 .78 0.13 
T-CHOL 50 148 280 198.70 33.69 
TGL 50 112 210 143.62 23.30 
HDL 50 25 56 34.64 8.01 
LDL 50 83.8 207.6 135.33 31.20 
VLDL 50 22.40 42 28.72 4.66 
LDH 50 110 162 139.58 13.69 
SGOT 50 28 98 60.64 22.94 
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ISCHEMIA MODIFIED ALBUMIN (Table VIII)  
Table VIII show Mann Whitney test for comparing Ischemia Modified Albumin  
between control  and study groups. The mean value of IMA for control and 
study group were 37.67±14.74 and 115.07±17.55 respectively . The  Mann 
Whitney U score was .000 and p value .000 (<0.01)  
 
 
 
 
Control 
Study 
37.61 
115.07 
Ischemia Modified Albumin (Fig 4) 
IMA Mean SD Mean rank Sum of 
rank 
Mann 
Whitney U 
score 
p value 
Control 37.61 14.74 25.5 1275 .000 .000 
< 0.01 
statistically 
significant 
Study 115.07 17.55 75.5 3775 
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CKMB (Table IX) 
 
CKMB Mean SD Mean 
rank 
Sum of 
rank 
Mann 
Whitney 
U score 
 p value 
Control 12.40 2.79 25.56 1278.00 3.000 .000 
Study 67.87 31.85 75.44 3772.00 
 
Table IX shows Mann Whitney test for comparing CKMB between control and 
study groups. The mean value of CKMB for control and study group were 
12.40±2.79 and 67.87±31.85 . The Mann Whitney U score was 3.000 and p 
value.000 (< .01). 
 
 
 
Control 
Study 
12.4 
67.87 
CK -MB (Fig 5)  
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STATISTICAL ANALYSIS OF OTHER PARAMETERS BETWEEN 
CONTROL AND STUDY GROUPS (Table X) 
 case 60.64 22.94 73.92 3696.00   
 Mean SD Mean 
Rank 
Sum of 
Ranks 
Mann 
Whitney 
U score 
Exact 
significance (p) 
S.ALBUMIN control 3.79 0.26 50.00 2500.00 1225 0.864 
case 3.80 .27 51.00 2550.00 
RBS control 110.8 8.68 34.28 1714.00 439 0 
case 142.24 33.28 66.72 3336.00 
UREA control 25.26 3.86 37.16 1858.00 583 0 
case 29.80 4.75 63.84 3192.00 
CREAT control 0.82 0.13 55.06 2753.00 1022 0.116 
case 0.78 0.13 45.94 2297.00 
T-CHOL control 149.92 25.07 29.95 1497.50 222.5 0 
case 198.70 33.69 71.05 3552.50 
TGL control 133.46 16.34 45.03 2251.50 976.5 0.059 
case 143.62 23.30 55.97 2798.50 
HDL control 40.70 4.78 63.55 3177.50 597.5 0 
case 34.64 8.01 37.45 1872.50 
LDL control 82.53 25.82 28.80 1440.00 165 0.059 
case 135.33 31.20 72.20 3610.00 
VLDL control 26.69 3.27 45.03 2251.50 976.5 0.059 
case 28.72 4.66 55.97 2798.50 
LDH control 108.04 34.28 35.76 1788.00 513 0 
case 139.58 13.69 65.24 3262.00 
SGOT control 25.44 5.68 27.08 1354.00 79 0 
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Correlation between IMA and other parameters in study 
group (TABLE X) 
IMA Spearman 
Correlation rho 
value 
p – values Statistical 
Inference 
S.ALBUMIN 0.230 0.108 Not significant 
CK – MB 0.665 0.000 Significant 
DURATION 0.639 0.000 
T- CHOL 0.185 0.197 Not 
Significant TGL 0.228 0.112 
HDL 0.144 0.319 
VLDL 0.228 0.112 
LDL 0.131 0.363 
LDH 0.270 0.058 Significant 
SGOT 0.355 0.011 
 
Table XI  shows the correlation between IMA  and other parameters in the study 
group. In this CKMB, LDH and SGOT showed significant correlation  with 
IMA. 
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FREQUENCY TABLE FOR DURATION AFTER ONSET OF 
ACS AND SERUM LEVELS OF  IMA AND CK-MB        
(TABLE XI) 
 Hrs  Total  
2 to 4 hours 4 to 8 hours count Col % 
count Col % count Col % 
IMA 
(U/L) 
Below 85 2 6.4 1 5.2 3 6 
Above 85 29 93.6 18 94.8 48 94 
CK-
MB(U/L) 
Below 24 12 38.7 1 5.2 13 26 
Above 24 19 62.8 18 94.8 37 74 
 
Table XI  shows the comparison of time duration and rise of IMA and CKMB . 
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                    SCATTER DIAGRAM : I 
 
Scatter diagram I  represents the correlation between serum Ischemia Modified 
Albumin  and CKMB in control group 
SCATTER DIAGRAM : II 
 
 
Scatter diagram II  represents the correlation between serum Ischemia Modified 
Albumin  and CKMB in study group. 
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SCATTER DIAGRAM : III 
 
Scatter diagram III represents the correlation between serum Ischemia Modified 
Albumin  and Total Cholesterol in control group. 
SCATTER DIAGRAM : IV 
 
 
Scatter diagram IV represents the correlation between serum Ischemia Modified 
Albumin  and Total cholesterol in study group. 
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SCATTER DIAGRAM : V 
 
Scatter diagram V represents the correlation between serum Ischemia Modified 
Albumin  and Triglycerides in control group. 
SCATTER DIAGRAM : VI 
 
 
Scatter diagram VI represents the correlation between serum Ischemia Modified 
Albumin  and Triglycerides in study group. 
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SCATTER DIAGRAM : VII 
 
Scatter diagram  VII represents the correlation between serum Ischemia 
Modified Albumin  and HDL- cholesterol in control group. 
SCATTER DIAGRAM : VIII 
 
Scatter diagram  VIII represents the correlation between serum Ischemia 
Modified Albumin  and HDL - cholesterol in study group. 
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SCATTER DIAGRAM : IX 
 
Scatter diagram  VIII represents the correlation between serum Ischemia 
Modified Albumin  and HDL - cholesterol in study group. 
SCATTER DIAGRAM : X 
 
Scatter diagram  X represents the correlation between serum Ischemia Modified 
Albumin  and LDL- cholesterol  in  study   group. 
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SCATTER DIAGRAM : XI 
 
Scatter diagram XI represents the correlation between serum Ischemia Modified 
Albumin  and VLDL in control group 
SCATTER DIAGRAM : XII 
 
Scatter diagram XI represents the correlation between serum Ischemia Modified 
Albumin  and VLDL in control group 
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SCATTER DIAGRAM : XIII 
 
Scatter diagram  XIII  represents the correlation between serum Ischemia 
Modified Albumin  and LDH in control group. 
  
          SCATTER DIAGRAM : XIV 
 
Scatter diagram  XIV   represents the correlation between serum Ischemia 
Modified Albumin  and LDH in study group. 
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SCATTER DIAGRAM : XV 
 
Scatter diagram  XV    represents the correlation between serum Ischemia 
Modified Albumin  and SGOT in control group. 
SCATTER DIAGRAM : XVI 
 
Scatter diagram  XVI  represents the correlation between serum Ischemia 
Modified Albumin  and SGOT  in study group. 
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SCATTER DIAGRAM : XVII 
 
 
Scatter diagram XVII  represents the correlation between serum Ischemia 
Modified Albumin  and time duration  in study  group. 
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DISCUSSION 
Coronary heart disease accounts for increasing mortality and morbidity 
worldwide. Acute Coronary Syndrome  is a subset which comprises of about 
20-23% of patients presenting at emergency department.
80
  
The diagnostic markers of AMI  established by the world health organisation in 
1986  included biomarkers  as an integral part of the disorder and required at 
least two of the following criteris be met: 
(1) a history of chest pain. 
(2) evolutionary changes on the ECG.  
(3) Elevations of serial cardiac markers to a level two times the normal value.    
However in over time , it became rare for a diagnosis of AMI to be made in the 
absence of myocardial injury.   
 A 2000 European Society of Cardiology / American College of Cardiology 
(ESC/ACC)
80
 consenses conference updated in 2007 (Global Task Force) 
codified the role of markers by advocating that the diagnosis should be regarded 
as evidence of myocardial injury based on  markers of cardiac markers in the 
appropriate clinical situation.
81
 The guidelines thus recognised the reality that 
neither the clinical presentation for the ECG findings had adequate sensitivity 
and specificity. Many studies have proposed that combined use more than one  
cardiac biomarkers along with clinical findings and ECG. 
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                           The biomarkers for early identification of myocardial injuries 
both ischemia and necrosis   in   Acute Coronary Syndrome (ACS) are 
necessary in the diagnosis and the treatment decision to prevent the associated 
complications as well as to reduce the mortality.  In the clinical practice, more 
attention has been paid to the estimation of serum levels of myocardial markers 
for the diagnosis of acute myocardial Ischemia, stratification of the ACS risk 
and the differential diagnoses of reversible versus irreversible myocardial 
ischemia and acute chest pain. The usefulness of biomarkers in ACS  depends 
on the presence of myonecrosis.  However , many patient with ACS  may have 
myocardial ischemia without myonecrosis .Although  currently available 
biomarkers sch as CK-MB, CK-MB mass trop-I , LDH, etc are useful in the 
diagnosis of ACS, they don’t seem to increase before necrosis of myocytes and 
are time dependent. Moreover these markers to increase in the serum require 
cell death and leakage of proteins out of the myocytes which takes  longer time 
for about 4 -6 hours. 
Ischemia Modified Albumin is one of the recently idendified  ischemic 
biomarker approved  by U.S Food and Drug Admnistration. 
82
 Myocardial 
Ischemia changes the structure of the N-terminus of serum albumin which 
makes it unable to bind metals and can be measured by Albumin Cobalt 
Binding assay. This was found to increase in blood within minutes of the onset 
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of myocardial ischemia , remain elevated upto 6 -12 hours and return to normal 
within 24 hours. 
In  2001 a multicentre study was done with 224 patients who arrived  in the 
emergency department within 3 hours of the onset of symptoms suggestive of 
Acute Coronary Syndrome and  the ability of ACB to predict positive and 
negative  cTrop I result with 6 -24 hours after presentation. At the optimum cut 
off for  the ACB test the sensitivity and specificity were 70% and 80% 
respectively, with a negative predictive value of 96%.  
One study of patients with suspected ACS found that IMA had a better Negative 
Predictive value  92% than with combination of CKMB, myoglobin amd cTnT 
(86%). the  sensitivity and specificity of elevated IMA for future mortality has 
been reported at 76% and 74%. 
Shaoguing Juand et al., showed that the IMA concentration had increased 
significantly in the UA patients. In addition, IMA was negatively correlated 
with an abnormal Left Ventricular Ejection Fraction (LVEF), which  was 
proved to be of clinically  significant  in the early diagnosis and the 
stratification of risk in patients with acute coronary syndromes. 
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                          In accordance with the above studies,  in the  study Ischemia 
Modified Albumin was increased earlier than CK-MB .  The mean CK-MB 
level in the study group was  (75.44±31.85 ) which is significantly higher than 
in the control group (25.56 ± 2.79)  and found to be increased after 4 hours of  
onset of chest pain.  But didnot show significant increase as IMA in the early 
hours of ischemia. The mean value of  IMA of the study group (115.07 ± 17.55) 
was signicicantly higher than the control group (37.61 ± 14.74). Increase in 
IMA value  and CK-MB was positively correlated in patients presented after 
hours. In this study ,  Ischemia modified albumin for the diagnosis of acute  
ischemic chest pain was significant along with other markers like increased 
CKMB and ECG findings. A biomarker of ischemia such as IMA  will improve  
early diagnosis and also to rule out patients who do not have ACS and also 
more than 50%  of patients presenting to the Emergency Department with chest 
pain were admitted to rule in or out Ischemic Heart Diease. Thus the serum 
levels of IMA can be used to both  for diagnosis and  rule in or rule out 
ischemic changes in the early hours. 
 The mean total cholesterol level in the study group (198.70± 33.69) was 
higher than the control group (149.92 ± 25.07) which was statistically  
significantly. This coincides with studies done by Mari Luomala et al and Lucie 
Locaste et al which suggested  that total cholesterol more than 150mg/dl as risk 
factor for cardiovascular events.  
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 The mean serum HDL –C which is lower in the study group compared to 
the control group (40.70± 4.78   verses  34.64 ± 8.01) which was statistically 
significantly (p < 0.05) and as per the recommendation of NCEP ATP III risk 
classification for HDL-C levels the serum  HDL –C <4omg/dl considered as 
high risk for IHD. 
 The mean values of LDL-C, VLDL, and TGL are also significantly 
increased in the  study group than the control group which contributes to 
increased risk  for CHD. 
 Pearson correlation analysis showed significant correlation between IMA 
with CK-MB , LDH,  SGOT and the duration within which it increases.   
                                The strength of this study includes the homogenecity of the 
study group with respect to exclusion of possible confounding clinical 
conditions and proper timing of blood sampling.  In this study mean value of 
IMA  of study group was significantly higher than the control group and 
elevated within 2-3 hours. The mean value of CK-MB also significantly 
elevated but only after 4-6 hours and elevation of CKMB was well correlated 
with rise in IMA. Furthermore all the predisposing factors like smoking 
hypertension dyslipidemia  , diabetes etc are present and significant number of 
patients are associated with these risk factors. 
The measurement of IMA was done by simple cost effective chemical method 
(Albumin Cobalt Binding Test)  and was approved by FDA. Elevation in IMA 
120 
 
identifies the early ischemic changes which will be reversible before irreversible 
necrosis occurs and are well correlated with CKMB levels also. The levels of 
IMA also was significantly higher than the healthy group and these results are 
in compliance with  many literature data. Thus serum levels of Ischemia 
Modified Albumin can be used to identify  ACS at an earlier stages which helps 
in Emergency Department to diagnose and to aid treatment decision. 
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CONCLUSION 
Biochemical markers such as CK-MB, Cardiac Troponin-I and Myoglobin are 
suitable only for assessing myocardial infarction. The results of the present 
study confirm the findings of previous studies, that reported that the Albumin 
Cobalt colorimetric assay distinguishes myocardial ischemic patients from non 
ischemic patients (p<0.001) 
IMA assay presents a quantitative accurate laboratory determination of the  
occurrence of an Ischemic myocardial event  including  angina of various types. 
Measurement of Ischemia Modified Albumin levels  diagnose Acute Coronary 
Syndrome in patients with ongoing myocardial ischemia in Emergency 
Department. Measuring IMA  along with ECG and other markers improves the 
diagnostic sensitivity of the method. 
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LIMITATIONS OF THE STUDY: 
Further multicentre cohort study  has to be done  to assess the physicians  in a 
better way in treatment decisions. 
This assay need to be evaluated by incorporating it into decision making 
algorithm in an emergency department. 
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FUTURE SCOPE OF THE STUDY: 
 
IMA level estimation in outpatient department itself can be done in patients 
complaining of chest pain to rule out myocardial ischemia before ECG 
manifestation especially in unstable angina, and other variants of Angina like 
Nocturnal Angina, prinzmetal’s variant Angina and stable exertional Angina. 
It can be also used to rule out non anginal causes of chest pain. If these 
observations are confirmed, IMA can be used as an outpatient investigation 
tool, to reduce in appropriate Hospital Admissions of Low risk patients. 
 
.  
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STUDY OF SERUM ISCHEMIA MODIFIED ALBUMIN IN ACUTE CORONARY 
SYNDROME –PROFORMA 
NAME OF THE PATIENT : 
 
AGE    : 
 
OCCUPATION  : 
 
ADDRESS   : 
 
COMPLAINTS  : 
 
PAST HISTORY  : 
 
PERSONAL HISTORY : 
 
FAMILY HISTORY  : 
 
DRUG HISTORY  : 
GENERAL EXAMINATION:          
                                               Ht:                Wt:            BMI:               BP:                 PR: 
 
SYSTEMIC EXAMINATION:      
                                            CVS:                                                   RS:                                                           
                                            ABD:                                                  CNS:                                                                                     
INVESTIGATIONS : 
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1.BLOOD SUGAR :       FBS:                               PPBS: 
 
2.SERUM ISCHEMIA MODIFIED ALBUMIN : 
 
3.SERUM CK-MB 
 
4.BLOOD UREA: 
 
5.SERUM CREATININE: 
 
6.LIPID PROFILE: 
 
TOTAL CHOLESTEROL: 
 
TRIGLYCERIDES: 
 
HDL: 
 
LDL: 
 
VLDL: 
SGOT: 
LDH 
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CONSENT FORM 
 
 
Dr .R.Freethi post graduate student in the department of Biochemistry, Thanjavur medical 
college, Thanjavur is doing a Study On Study of serum levels of ischemia modified albumin 
in acute coronary syndrome. The procedures has been explained to me clearly. I understand 
that there are no risks involved in the above procedures. I hereby give my consent to 
participate in this study. The data obtained here may be used for research and publication. 
 
Signature : 
 
Name: 
 
Place:  
 
 
